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During myogenic differentiation, proliferating myoblasts undergo a pre-requisite 
step of irreversible cell cycle exit prior to differentiation to form multinucleated 
myotubes. MyoD, a key regulator of muscle differentiation, mediates cell cycle exit 
as well as expression of differentiation specific genes. Studies from our lab have 
identified that G9a/EHMT2, a lysine methyltransferase, is expressed in skeletal 
myoblasts and inhibits myogenic differentiation. G9a, when overexpressed, 
mediates repressive histone-3 lysine-9-di-methylation (H3K9me2) on myogenin 
promoter. In addition, G9a also methylates MyoD and inhibits its transcriptional 
activity. While G9a overexpression inhibits myogenic differentiation, its role in 
regulating proliferation and cell cycle exit is not clear. Besides, the genome wide 
molecular targets of G9a in muscle cells are unknown. 
In order to identify G9a targets globally, we performed gene expression analysis 
using microarrays. Interestingly, knockdown of G9a in myoblasts altered several 
genes involved in cell cycle control. Hence, we examined if G9a has a role in 
regulating proliferation of cells. Using cultured myoblast lines, as well as primary 
myoblasts from wild type and G9a conditional knockout mice, we found that G9a 
promotes proliferation of cells. G9a knockdown up regulated p21Cip1/Waf1 (p21) and 
Rb1, which are required for cell cycle exit but also led to the down regulation of 
several E2F1 target genes. We therefore hypothesized that G9a may regulate 
myoblast proliferation in two distinct mechanisms: (1) Repression of p21 and Rb1 




Consistent with its function as a transcriptional repressor, G9a inhibited expression 
of p21 and Rb1 in methyltransferase-dependent manner during differentiation by 
mediating H3K9me2 marks on their promoters. Moreover, G9a mediated inhibition 
of myogenic differentiation was rescued by re-expression of p21 and Rb1.  
To examine whether G9a actively promotes the expression of cyclins and other 
E2F1 target genes, we examined its occupancy on E2F1 target gene promoters. 
Remarkably, unlike p21 and Rb1 promoters, G9a occupancy was not correlated 
with repressive H3K9me2 on E2F1-target genes. Moreover, pharmacological 
inhibition of endogenous G9a methyltransferase activity did not significantly 
change expression of E2F1 target genes. Consistent with this, H3K9me2 on their 
promoters were unaltered. G9a occupancy was associated with H3K9ac instead. 
Furthermore, protein-protein interaction studies indicated that G9a complexes with 
the histone acetyltransferase P/CAF and E2F1 in myoblasts. Consistent with these 
findings, myoblasts isolated from G9a conditional knockout mice displayed 
reduced proliferation. Cell cycle exit genes were up-regulated and E2F1 target 
genes were down regulated validating our in vitro findings.   
Overall our data support a model in which G9a both prevents cell cycle exit and 
promotes proliferation of muscle cells to block differentiation. These studies 
implicate that G9a may be de-regulated in myopathies associated with an imbalance 
of proliferation and differentiation, and suggest that targeting G9a may be a 
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The ability of living organisms to perform any type of body movement is attributed 
to the muscle tissue. Muscle tissue consists of cells arranged into muscle fibers 
which are capable of contracting and relaxing. Muscle tissue is categorized into 
three types – smooth muscle, cardiac muscle and skeletal muscle. Smooth muscles 
are non-striated muscle found intrinsically covering internal organs of the body. 
Cardiac muscles exhibit striations and are found in the heart. Skeletal muscle is also 
striated muscle, but unlike cardiac muscle, it can be voluntarily controlled. It is 
attached to the skeleton and is the most abundant tissue in the vertebrate body, 
accounting for approximately 40 percent of total body mass in adults.  
During embryonic development, skeletal muscle is formed through a process called 
myogenesis (Bentzinger et al., 2012). Myogenesis is achieved through signaling 
molecules from adjacent tissues that specifies myogenic cell fate and requires 
spatial-temporal regulation of proliferation and differentiation of embryonic 
precursor cells (Buckingham, 2001; Zhang et al., 1999). In skeletal muscle cells 
proliferation and differentiation processes are coupled yet mutually exclusive. Cell 
cycle arrest is an essential step during muscle differentiation. Thus skeletal 
myogenesis serves as an exquisite paradigm to understand the cell cycle regulatory 




1.1 Embryonic myogenesis 
 
During gastrulation, the three germ layers ectoderm, endoderm and mesoderm are 
formed from pluripotent epiblast cells at the primitive streak (Beddington and 
Smith, 1993). Expression of key regulatory genes leads to the commitment of cells 
to different lineages. At the anterior part of primitive streak, paraxial mesoderm 
undergo segmentation, leading to the formation of an epithelial ball of cells called 
somites (Tajbakhsh and Cossu, 1997). In mice, somitogenesis begins from 
embryonic day eight (E8) and the newly formed somites mature in a rostro-caudal 
developmental gradient, differentiating to give rise to the dorsal epithelial 
dermomyotome and the ventral mesenchymal sclerotome (Fig 1.1A). Vertebral 
column, cartilage and ribs are formed from the sclerotome whereas skeletal muscles 
of the trunk and limbs are derived from skeletal muscle progenitor cells of the 
dermomyotome. A few cells migrate from the dorsomedial part of the somites under 
the dermomyotome to form the myotome. These cells undergo sequential steps of 
myoblast amplification, cell cycle arrest and differentiation to form the first skeletal 





Figure 1.1A Schematic representation of vertebrate somitogenesis in mouse 
embryo (Buckingham, 2001).  The paraxial mesoderm segments in a rostro-caudal 
gradient on either side of neural tube and notochord to form an epithelial ball of 
cells called somites.  Skeletal muscle is formed from the embryonic progenitor cells 
arising from somites. Several signaling pathways arising from adjacent tissues lead 
to the specification of embryonic precursor cells to myogenic fate, forming 
dermomyotome and sclerotome. A few cells migrate under the dermomyotome to 
form the myotome which later differentiates to form skeletal muscle in the embryo.  
 
The skeletal muscles at different stages - embryo, fetal and postnatal - appear to 
form through a sequence of steps involving embryonic myoblasts, fetal myoblasts 
and postnatal satellite cells (Tajbakhsh, 2003) (Fig 1.1B). Around embryonic day 
11 (E11), the post-mitotic myocytes at the myotome fuse to form multinucleated 
primary myofibers, in the process known as primary or embryonic myogenesis. 
Later around embryonic day E14.5 and E17.5 a second wave of myogenesis called 
secondary myogenesis occurs, involving fusion of fetal myoblasts to form 
secondary myofibers. Each of these myofibers is surrounded by a basal lamina. At 
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this stage, muscle stem cells, or satellite cells, are formed beneath the basal lamina 
and myofiber plasma membrane (Tajbakhsh, 2003; Cossu et al., 1996) (Fig 1.1B).  
 
Figure 1.1B Schematic representation of muscle development from skeletal 
muscle stem cells (Tajbakhsh, 2003). Muscle progenitors at somites disperse as 
embryonic, fetal, and satellite cells leading to the formation of skeletal muscle in 
the body. The primary fibers formed from embryonic myoblasts act as scaffold for 
secondary fibers which arise from fetal myoblasts. These secondary fibers form the 
bulk of skeletal muscle in the postnatal period. Satellite cells are found in adults 
and are crucial for muscle regeneration.   
1.2 Adult myogenesis   
 
In 1961, Alexander Mauro first identified mononucleated cells attached to the basal 
lamina of the myofiber. Based on its anatomical location, sub laminar, these cells 
were named as satellite cells (Mauro, 1961). Satellite cells arise from muscle 
progenitor cells expressing Pax3 and Pax7 at the dermomyotome (Kassar-
Duchossoy et al., 2005). Satellite cells are non-proliferative and quiescent in nature. 
However, emerging evidence indicates that these cells are metabolically and 
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transcriptionally active. The remarkable ability of skeletal muscles to regenerate is 
credited to the presence of satellite cells (Buckingham, 2001; Tajbakhsh, 2003).  
In vivo, upon injury or trauma to the muscle tissue, satellite cells get activated to 
enter into the cell cycle, proliferate and give rise to myoblasts which later exit cell 
cycle irreversibly and fuse to repair the damaged myofiber (Schultz and 
McCormick, 1994) (Fig 1.2). Owing to its stem cell properties, satellite cells have 
the ability to self-renew (Potten and Loeffler, 1990). A few progenitor cells undergo 
reversible cell cycle exit to form new quiescent satellite cells, thus maintaining the 
satellite cell numbers (Dhawan and Rando, 2005). Whereas a few other cells 
undergo irreversible cell cycle exit leading to the activation of differentiation 
specific genes and form new myofibers  
 
Figure 1.2 Schematic representation of muscle regeneration in vivo.  During 
muscle regeneration quiescent satellite cells get activated to enter cell cycle and 
proliferate to form transit amplifying myoblasts.  A few cells undergo reversible 
cell cycle exit and go back into quiescence, forming satellite cells.  Majority of 










1.3 Signaling pathways regulating myogenesis  
 
During somitogenesis, fine tuning of mesodermal progenitors to myogenic lineage 
has been attributed mainly to these signaling pathways: Wnt, Shh, Notch and BMP 
(Bentzinger et al., 2012). Wnt and Shh secreted by the dorsal neural tube and 
notochord are known to be involved in positive regulation of muscle differentiation 
and sclerotome formation. Wnt1 and Wnt3a are secreted from dorsal neural tube 
whereas Wnt4, Wnt6 and Wnt7a are secreted from surface ectoderm. Expression 
of Wnt receptors frizzled fzd7 is seen in the hypaxial region of somite whereas 
expression of fzd1 and fzd6 is seen in the epaxial region (Borello et al., 1999).  At 
the myotome, Wnt1 and Wnt3a activate myogenesis through TCF/β-catenin 
pathway and Wnt7a is known to induce myogenesis through β-catenin independent 
signaling pathways (Brunelli et al., 2007; Borello et al., 2006). Wnt1 and Wnt3a 
deficient mice show defect in the formation of the dermomyotome (Ikeya and 
Takada, 1998), and consistent with this, Wnt1 or Wnt3a over expression in chick 
somites activates genes involved in myogenesis (Tajbakhsh et al., 1998). 
Collectively, these studies indicate the importance of Wnt signaling pathway in 
myogenesis.   
Sonic hedgehog (Shh) released from the notochord of the neural tube is also 
involved in positive regulation of skeletal myogenesis. Shh knockout mice show 
defect in formation of distal limb structures and sclerotome formation (Zhang et al., 
2001; Chiang et al., 1996). Wnt and Shh pathway positively regulates myogenesis 
whereas BMP and Notch pathway are known to be involved in negative regulation 
of myogenesis (Bentzinger et al., 2012). Bmp4, which is expressed in the 
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mesoderm, appears to inhibit the expression of myogenic determination genes, 
indicating that BMP signaling is involved in the expansion of progenitor 
population. Correspondingly, expression of BMP antagonist Noggin at the 
dermomyotome initiates the expression of myogenic transcription factors leading 
to formation of myotomal cells (Reshef et al., 1998). Notch signaling has been 
implicated in regulating somitogenesis.  It is required for vertebrate segmentation 
and somite patterning (Lewis et al., 2009).  It has been shown that Notch ligand 
Delta1 mutant embryos show more myoblasts differentiation and have excess 
myofibers (Schuster-Gossler et al., 2007), suggesting that Notch signaling is 
involved in inhibiting the differentiation program. Overall the above studies 
suggest that extrinsic signaling pathways play important roles in specifying 
embryonic precursor cells to myogenic lineage.   
1.4 Transcription factors involved in skeletal myogenesis 
 
1.4.1 Paired homeobox transcription factors (Pax3 and Pax7) 
 
Along with extrinsic signaling pathways from adjacent tissues, several intrinsic 
regulatory factors are involved in specification and differentiation of skeletal 
muscle cells. The process of skeletal myogenesis is coordinated by several 
myogenic transcriptional factors. Pax3 and Pax7 mark progenitor cells in 
dermomyotome, and at embryonic day E9.75, almost all cells are positive for both 
these transcription factors. Higher expression of Pax3 is seen in dorsal and ventral 
dermomyotome lips whereas Pax7 expression is seen in central dermomyotome 
(Kassar-Duchossoy et al., 2005). Pax3 plays a role in progenitor cell formation as 
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well as in migration of cells to limb and other muscle structure in the body 
(Buckingham and Rigby, 2014; Cossu et al., 1996; Messina and Cossu, 2009). The 
mouse mutant Splotch (Pax3 null mice) fail to develop limb muscle indicating the 
importance of Pax3 in migration of progenitor cells (Daston et al., 1996; Strachan 
and Read, 1994). Moreover, ablation of Pax3+ cells led to the loss of all embryonic 
myofibers indicating the importance of Pax3 in embryonic myogenesis (Hutcheson 
et al., 2009). However, Pax7 null mice display normal skeletal muscle 
development, but completely lack satellite cells (Seale et al., 2000). This indicates 
the redundancy in roles played between Pax3 and Pax7 during embryonic 
development. In Pax3 and Pax7 double knockout mice, muscle development is 
arrested and only the early myotome is formed (Relaix et al., 2005).  Pax3+ cells in 
the limb can give rise to both muscle as well as endothelial lineage cells whereas 
Pax7+ cells can give rise to only myogenic cells (Hutcheson et al., 2009). Pax7+ 
cells are derived from Pax3+ cells and loss of Pax3 lineage is embryonically lethal 
whereas loss of Pax7 only leads to smaller muscle formation with fewer myofibers 
at birth (Seale et al., 2000). These studies suggest that Pax3 is critical for embryonic 
muscle formation and Pax7 for specification of myogenic satellite cells. Muscle 
precursor cells arising from dermomyotome express proto-oncogene c-Met which 
helps in cell migration and muscle formation (Cossu et al., 1996). Studies suggest 
that Pax3 regulate c-Met transcription, which is in turn required for cell migration 
of limb precursor cells (Epstein et al., 1996). Myogenic satellite cells are known to 
express c-Met receptors which is involved in hepatocyte growth factor signaling 
and activation of quiescent satellite cells (Allen et al., 1995).   
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1.4.2 Myogenic regulatory factors (MRFs) 
 
Embryonic muscle progenitor cells expressing Pax3 and Pax7 cannot initiate the 
differentiation program, suggesting the involvement of other factors in driving the 
differentiation process. Isolation of myoblast specific cDNAs led to the discovery 
of MyoD1, Myoblasts determination gene number 1 (Davis et al., 1987). MyoD, 
when transfected into the fibroblasts, has the ability to convert them into fusion 
capable myoblasts (Davis et al., 1987). This discovery paved way to understand the 
molecular mechanisms behind myogenic differentiation. Similarly, identification 
of three other factors, namely Myf5, Myogenin and MRF4, helped in better 
understanding of the skeletal muscle differentiation program (Edmondson and 
Olson, 1989; Braun et al., 1989; Braun et al., 1990). All these factors MyoD, Myf5, 
Myogenin and MRF4 are highly conserved and are collectively called as Myogenic 
Regulatory Factors (MRFs). Each MRF, when expressed in fibroblasts, has the 
ability to convert them into myoblasts (Braun et al., 1990). MRFs are basic helix 
loop helix transcription factors which contain a DNA binding domain and a 
dimerization domain. MRFs, through their helix loop helix region, dimerize with 
ubiquitously expressed E proteins such as E47 and E12. Once dimerized, the basic 
region of MRF-E heterodimers binds to the E box elements CANNTG on the 
muscle promoters and drives the muscle differentiation program (Singh and 
Dilworth, 2013; Lassar et al., 1989).   
In somites, Myf5 is expressed first in muscle progenitor cells followed by MyoD, 
leading to the formation of proliferating myoblasts (Buckingham and Tajbakhsh, 
1993). Subsequently, Myogenin and MRF4 are expressed during terminal 
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differentiation (Cossu et al., 1996; Ott et al., 1991). However, expression of MRF4 
has been observed in three waves during myotomal expansion (My1, My2 and 
My3). My1 begins at embryonic day 8 (E8), My2 at embryonic day 9 (E9) and the 
final one at embryonic day 16 (E16) (Patapoutian et al., 1995). The role of MRFs 
in muscle development has been well characterized. Mice lacking either Myf5 or 
MyoD have normal skeletal muscle development, suggesting the redundancy in 
roles played by these two factors (Braun et al., 1992). However, mice lacking both 
are devoid of skeletal muscle as well as myogenic precursor cells (Rudnicki et al., 
1993). Mice lacking myogenin show normal muscle development at early stages, 
however, during later stages they show impairment in the myofiber formation and 
the mice die perinatally (Hasty et al., 1993; Nabeshima et al., 1993). This is 
highlighted by the fact that myogenin knockout myoblasts are able to undergo cell 
cycle exit, but cannot fuse to form myotubes. MRF4 null mice display multiple rib 
abnormalities with increased myogenin expression. This suggest that myogenin 
may compensate for the loss of MRF4 (Zhang et al., 1995).  
Overall, Pax3 appears to be on top of hierarchy where Pax3 positive cells give rise 
to initial myofibers and Pax7 positive cells contribute to formation of secondary 
myofibers and are involved in adult muscle regeneration through maintenance of 
satellite cell population in adults (Figure 1.1B). Myf5 and MyoD act upstream of 
Myogenin and MRF4, where Myf5 and MyoD are involved in myogenic 
determination while Myogenin, MRF4 are involved in differentiation. However 
recent evidences indicate that sine oculis related homeobox 1 (Six1) and Six4 are 
involved in specifying dermomyotomal cells towards myogenic lineage and are 
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considered to be at the quintessence of this transcriptional regulatory cascade 
(Bentzinger et al., 2012; Kawakami et al., 2000) (Figure 1.4).   
 
 
Figure 1.4 Schematic representation of transcription factors involved in 
myogenic lineage formation (Bentzinger et al., 2012). Myoblasts are formed from 
embryonic progenitor cells. A few progenitors remain as satellite cells in postnatal 
muscle forming adult muscle stem cells required for regeneration. During 
regeneration, some of the activated satellite cells can enter into quiescent state to 
maintain the satellite cell pool.  Pax3, -7 and Six-1, -4 are involved in muscle 
lineage specification and stand at top of the hierarchy. Myf5 and MyoD commit 
cells to muscle differentiation program whereas Myogenin and MRF4 are 
expressed during terminal differentiation during muscle formation.   
 
1.5 In vitro myogenic differentiation  
 
In vitro, myogenic cell lines such as rat L6 and mouse C2C12 cells are commonly 
used to study muscle differentiation. C2C12 myoblasts were originally derived 
from satellite cells of thigh muscle of C3H mouse (Yaffe and Saxel, 1977). Later 
immortal sub-line C2C12 was selected (Blau et al., 1985). C2C12 cells are cultured 
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under high serum condition to maintain them in proliferation state. Upon serum 
withdrawal, myoblasts turn on differentiation specific genes and fuse to form 
multinucleated myotubes. The process of differentiation is orchestrated by the 
sequential expression of myogenic regulatory factors MRFs including MyoD, 
Myf5, Myogenin and MRF4 and MEF2 family of transcription factors which 
includes MEF2-A, -B, -C and -D (Black and Olson, 1998). In addition, it is now 
well established that chromatin regulators associate with MRFs to reprogram 
chromatin at the promoters of muscle specific genes driving the differentiation 
program (Bharathy et al., 2013).   
Under in vitro conditions, proliferating myoblasts express MyoD and Myf5. Upon 
differentiation, myogenin is expressed at early stage, and then during myoblasts 
fusion, MRF4 and other structural proteins such as troponinT and myosin heavy 
chain (MHC) are expressed. MEF2 is expressed at lower levels compared to MRFs 
in proliferating myoblasts and their expression increases during differentiation. 
MEF2D is expressed at higher levels in undifferentiated cells compared to MEF2C. 
Myogenin and MEF2C are known to exist in a positive feedback loop promoting 
their expression and regulating the expression of structural genes required for 
terminal differentiation (Yee and Rigby, 1993). 
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For myogenic differentiation to occur, myoblasts need to exit the cell cycle 
irreversibly and like in most of the cells, proliferation promoting genes have to be 
suppressed. This type of exit is irreversible because the differentiated cells cannot 
re-enter the cell cycle or proliferate (Fig 1.5). Irreversible cell cycle arrest or 
permanent withdrawal from the cell cycle is an important pre-requisite step during 
skeletal muscle differentiation. Myoblasts also have the ability to undergo 
reversible exit leading to quiescence. Upon induction with quiescence signals, 
myoblasts exit the cell cycle reversibly, forming quiescent cells (Sachidanandan et 
al., 2002) (Fig 1.5). Upon addition of proliferation cues quiescent cells can reenter 
cell cycle and proliferate. Quiescent myoblasts mimic the characteristic of muscle 
progenitor cells.  
Figure 1.5 Schematic representation of in vitro myogenic differentiation. 
Proliferating myoblasts express MyoD and Myf5. Upon differentiation, cells 
undergo irreversible cell cycle exit mediated by p21 and Rb1.  Subsequently, 
expression of Myogenin leads to differentiation of cells forming myocytes.  Later 
myocytes fuse to form multinucleated myotubes expressing myosin heavy chain 
and troponin T.  Proliferating myoblasts can also enter into quiescence through 
reversible cell cycle exit. These cells mimic the characteristics of muscle stem cells 




1.6 Mechanisms underlying irreversible cell cycle exit during 
differentiation 
 
Apart from MRFs expression, cell cycle regulation seems to play a major role 
during muscle differentiation. Differentiation of myoblasts to multinucleated 
myotubes is coordinated by cell cycle genes as well as MRFs. Studies suggest that 
the process of cell cycle exit and differentiation are coupled in skeletal muscle cells 
(Nadal-Ginard, 1978). The role of cyclin kinase inhibitors such as p21 and Rb1 has 
been implicated in the process of cell cycle arrest during terminal differentiation 
(Mal et al., 2000). These proteins function by binding to Cyclin-CDK complexes 
and inhibiting their function leading to cell cycle arrest.  
During differentiation RNA and protein levels of p21 is significantly upregulated 
(Parker et al., 1995).  In general, p53 dependent induction of p21 is known to induce 
cell cycle arrest in various tissues. However, in skeletal muscle cells, MyoD 
upregulates p21 leading to the irreversible cell cycle exit. Indeed, over expression 
of MyoD in p53 null fibroblasts activates p21 promoter leading to terminal 
differentiation (Halevy et al., 1995).  Although MyoD mediated activation of  p21 
in skeletal muscle cells is important for cell cycle exit and differentiation, p21 null 
mice develop normally and do not show any skeletal muscle defect, however mice 
lacking both p21 and p57 fail to form skeletal muscle (Deng et al., 1995; Zhang et 
al., 1999). This suggests that both p21 and p57 play redundant role in controlling 
muscle differentiation. High p21 expression in myotubes leads to reduced kinase 
activity and thereby reduces the phosphorylation of Rb1 and in part maintaining the 
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permanent cell cycle arrest (Guo et al., 1995).  Hence, one of the other functions of 
p21 is to render Rb1 in hypo phosphorylated form.   
In general, Rb/E2F1 pathway seems to be the major pathway controlling the G1/S 
transition of cells (Chan et al., 2001). E2F1 transcription factor helps in driving 
G1/S transition during proliferation by activating its target genes such as Cyclin 
D1, Cyclin E as well as genes involved in DNA synthesis such as DHFR (Watanabe 
et al., 1998; Ohtani et al., 1995; Nevins, 1998). During G1/S transition, hyper 
phosphorylation of Rb1 releases E2F1 from the Rb-E2F1 complex, which allows 







Figure 1.6A Schematic representation of role of Rb/E2F1 pathway in 
mammalian cell cycle. Cell cycle can be broadly classified into G1, S and G2/M 
phase.  At late G1, just before restriction point (R) cells can enter into 
differentiation otherwise moves on to S phase.  In G1 phase, cell cycle progression 
is controlled by CyclinD1/CDK4 and CyclinE/CDK2 complex which in turn are 
regulated by Cyclin dependent kinases belonging to INK4 and CIP/KIP family. 
Phosphorylation of Rb by CyclinD1/CDK4, CyclinD1/CDK6 and CyclinE/CDK2 
complex releases E2F1 from Rb/E2F1 complex. Free E2F1 then induces the 




Since Rb phosphorylation is important for E2F1 to drive cell cycle, G1 Cyclins 
such as CyclinD1/CDK4, CyclinE/CDK2 complexes appear to play a significant 
role in Rb1 hyper phosphorylation (Mittnacht, 1998). G1 phase Cyclin/CDKs not 
only mediate Rb1 phosphorylation and help in G1/S transition, but they are also 
known to restrain MyoD activity in proliferating myoblasts and thereby avoid 
premature differentiation (Guo and Walsh, 1997). Indeed, forced expression of 
Cyclin D1 in cells has been shown to inhibit MyoD activity (Skapek et al., 1995). 
Therefore CyclinD1/CDK4 complex acts as one of the mechanisms restraining 
MyoD activity in myoblasts.  
In addition to the role of Rb1 in negatively regulating E2F1 target genes, Rb1 has 
been shown to be involved in cell cycle exit as well as activating muscle specific 
genes, suggesting the importance of Rb1 as a key protein regulating cell cycle and 
differentiation (Gu et al., 1993; Novitch et al., 1996). Myogenic regulatory factors 
fail to mediate myogenic conversion and cell cycle exit in Rb null cells, indicating 
the importance of Rb during myogenic differentiation. Rb null mice show normal 
muscle development. However, early lethality in these mice before embryonic day 
E14.5 has restricted our understanding of the role of Rb in secondary myogenesis 
(Clarke et al., 1992).  Rblox mice expressing low levels of Rb driven by Rb mini 
gene can be rescued to birth. The Rb mutant mice fetuses die at birth and show 
defect in skeletal muscle including shorter myotubes, fewer myofibrils, reduced 
myofibers and DNA synthesis in myotube nuclei (Zacksenhaus et al., 1996).   
During differentiation, MyoD is involved in increase of Rb1 gene expression and 
studies also show that Rb interacts with MyoD to help in increasing MEF2 
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transcriptional activity (Gu et al., 1993; Novitch et al., 1999). The levels of hypo 
phosphorylated form of Rb1 increases during differentiation, which helps in 
blocking proliferation of cells. Myotubes derived from Rb-/- mice fail to maintain 
the permanent exit state and display DNA synthesis after re-addition of serum to 
the cultures (Mal et al., 2000). Furthermore, inactivation of p21 and Rb1 by binding 
of E1A adenovirus protein has been shown to induce DNA synthesis in myotubes 
(Mal et al., 2000). Hence both p21 and Rb1 are important for cell cycle exit and 
maintenance of permanent cell cycle arrest in differentiated myotubes.   
To summarize, during the process of differentiation, proliferating myoblasts 
irreversibly exit the cell cycle, undergo permanent arrest and subsequently express 
differentiation specific genes. This indicates that for MyoD mediated 
differentiation, down regulation of E2F1 mediated proliferation genes is necessary. 
E2F1 is generally observed as master regulator for cell cycle control (La Thangue, 
1994). Under growth conditions, E2F1 is active in myoblasts and drives the 
expression of its target genes required for proliferation, while MyoD activity is 
suppressed.  However, upon differentiation cues, MyoD is activated and cell cycle 
arrest is achieved through induction of cell cycle inhibitors p21 and Rb1 while E2F1 
activity is suppressed (Fig 1.6B).  Therefore regulation of MyoD and E2F1 activity 
is required during proliferation and differentiation and epigenetic mechanisms 

















Figure 1.6B Schematic representation of E2F1 and MyoD function during 
proliferation and differentiation of myoblasts. In proliferating myoblasts, MyoD 
is inactive whereas E2F1 is active in transcribing genes required for proliferation.  
During differentiation, E2F1 is inactive and MyoD is activated to transcribe genes 





1.7 Transcriptional control and epigenetic regulation of 
proliferation and differentiation 
 
Although MyoD, the master regulator of differentiation, is expressed in 
proliferating myoblasts, various mechanisms exist to regulate its activity to avoid 
premature differentiation. For instance, MyoD forms heterodimers with E proteins 
(E12 and E47) and bind to E box elements on muscle gene promoters and drives its 
target gene expression (Lassar et al., 1991). However, Id1 (inhibitor of DNA 
binding) proteins, prominently induced in high serum conditions, forms inactive 
heterodimers with E box proteins E12 and E47, thus sequestering the E proteins 
and preventing the formation of the functional MyoD-E heterodimers (Benezra et 
al., 1990). Other b-HLH transcription factors such as Twist are also known to 
inhibit MyoD activity through E protein sequestration as well as inhibiting MEF2 
activity (Spicer et al., 1996).  Similarly MyoR and several other signaling factors 
such as TGFs and FGFs seems to regulate myogenic differentiation (Florini and 
Magri, 1989). Sharp1, a basic helix loop helix transcription factor expressed in 
myoblasts, is also known to inhibit MyoD transcriptional activity through 
recruitment of chromatin modifiers (Azmi et al., 2004; Ling et al., 2012a).  In 
addition, phosphorylation of MyoD by Cyclin kinases at different phases of cell 
cycle appears to negatively regulate the activity of MyoD as well as its turnover 
(Batonnet-Pichon et al., 2006). MyoD expression peaks at G1 as well as during 
early M phase of the cell cycle and myoblasts enter the differentiation program 
during G1 phase. During G1/S transition, MyoD becomes phosphorylated at serine 
residue 200, which signals for ubiquitination of MyoD and its degradation. 
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Similarly, MyoD phosphorylation during G2/M transition leads to its degradation 
(Batonnet-Pichon et al., 2006; Kitzmann et al., 1998).   
At the chromatin level, muscle specific DNA sequences are packaged by histones 
and non-histone proteins to form chromatin. This condensed nucleosomal structure 
at muscle promoters prevents the access to the transcription factors such as MyoD 
resulting in transcriptional repression of muscle specific genes. Therefore dynamic 
changes at chromatin level are required for association or dissociation of 
transcription factors. These modifications are brought about through various post 
translational modifications of histone tails such as acetylation, phosphorylation and 
methylation (Lachner et al., 2003). In general, acetylation of histone tails leads to 
open chromatin conformation and hence is associated with transcriptional 
activation of genes whereas histone methylation is associated with transcriptional 
repression.   
In undifferentiated proliferating myoblasts, various chromatin regulators create a 
repressive environment on muscle promoters, thereby restraining MyoD and MEF2 
transcriptional activity.  However, at the same time, E2F1 is active in driving the 
expression of proliferation genes (De Falco et al., 2006).  Chromatin regulators and 
remodeling complexes such as HDACs, HATs, HMTs and SWI/SNF complexes 
cooperate with MyoD and E2F1 factors to bring changes at the promoters of 
differentiation as well as proliferation specific genes to regulate their expressions 






Figure 1.7 Schematic representation of epigenetic regulation of MyoD and 
E2F1 target genes during proliferation and differentiation. In proliferating 
myoblasts MyoD is associated with co-repressors rendering it transcriptionally 
inactive whereas E2F1 is associated with co-activators leading to the expression of 
its target gene.  During differentiation MyoD associates with co-activators whereas 
E2F1 is inactive due to its association with co-repressors.  
 
During proliferation, Class I and Class II HDACs which are expressed in 
proliferating myoblasts are known to negatively regulate MyoD activity. MyoD 
transcription activity is known to be repressed due to its association with class I 
HDACs in proliferating myoblasts, which leads to MyoD deacetylation as well as 
deacetylation of histone tails at target promoters (Puri et al., 2001; Mal and Harter, 
2003; Mal et al., 2001). In addition, MEF2 associates with class II HDACs (HDAC 
4 and HDAC 5) and thereby MEF2 transcriptional activity is repressed in 
undifferentiated cells (McKinsey et al., 2001). Similarly Class III HDACs (Sir2) 
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are also known to negatively regulate myogenesis by functioning as redox sensor. 
Sir2, when over expressed, associates with P/CAF and MyoD and inhibit muscle 
gene expression (Fulco et al., 2003).  
Furthermore, in addition to HDACs, muscle promoters in proliferating myoblasts 
are repressed by SET domain containing histone methyltransferases (Zhang et al., 
2002). Histone methyl transferases such as Suv39h1 and G9a mediate repressive 
H3K9 methylation on the muscle promoters and thereby represses muscle gene 
expression (Mal, 2006; Ling et al., 2012b). Suv39h1 is known to interact with 
MyoD and repress its activity as well as myogenic differentiation. H3K9 
methylation of the muscle promoters signals the recruitment of HP1 leading to the 
formation of heterochromatic structure which represses muscle gene transcription 
(Mal, 2006).  Recently our lab has found that G9a, a euchromatic HMTase, is 
expressed in undifferentiated myoblasts and its expression declines upon 
differentiation. G9a mediates H3K9me2 on myogenin promoter as well as 
methylates MyoD directly, thereby repressing its transcriptional activity (Ling et 
al., 2012b).   
In contrast to the negative regulation of MyoD activity during proliferation, E2F1 
actively transcribes genes involved in cell cycle progression. E2F1 is found in 
association with transcriptional co-activators such as p300/CBP and P/CAF (De 
Falco et al., 2006; Trouche et al., 1996). p300/CBP and P/CAF are histone 
acetyltransferases known to be involved in mediating acetylation (Ogryzko et al., 
1996). Acetylation of E2F1 by P/CAF and p300 enhances DNA-binding ability of 
E2F1 and its transcriptional activity (Martínez-Balbás et al., 2000).  
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Differentiation requires replacement of all the repressive marks at muscle specific 
genes seen in undifferentiated myoblast with activation marks. Upon differentiation 
cues, the transition of cells from proliferation to differentiation requires permanent 
withdrawal from cell cycle as well as down regulation of inhibitory factors 
controlling MyoD activity. This transition is achieved through down regulation of 
Cyclins and inhibitory factors such as Id, Twist, and MyoR with up regulation of 
cell cycle inhibitors such as p21 and Rb1. MyoD becomes active whereas E2F1 
activity is inhibited. This seems to be achieved by an interplay between the co- 
activator and co-repressor complexes on target promoters. MyoD complexes with 
p300/CBP and P/CAF and drives the muscle gene expression (Puri et al., 1997; 
Sartorelli et al., 1999)  whereas E2F1 is found to be in repressive complex with Rb1 
and HDAC leading to the repression of proliferation genes (Blais et al., 2007; De 
Falco et al., 2006). In addition to HDACs and Rb1, Suv39h1 is shown to be 
involved in silencing S phase genes in differentiated cells (Ait-Si-Ali et al., 2004).  
Collectively, these studies indicate the importance of chromatin modifiers in 
regulating proliferation and differentiation of skeletal myoblasts. Our lab has been 
particularly interested in understanding the role of a chromatin modifier G9a in 




1.8 Mechanisms of repression by G9a, a lysine methyl 
transferase 
 
G9a/EHMT2 belongs to the Su (var) 3-9 family of proteins which includes 
Suv39h1/h2, SETDB1and SETDB2 (Tachibana et al., 2001; Dillon et al., 2005). 
These proteins contain an evolutionarily conserved SET domain required for their 
methyltransferase activity and an ankyrin repeat domain required for protein-
protein interaction (Brown et al., 2001; Milner and Campbell, 1993; Tachibana et 
al., 2001) (Fig 1.8). G9a is known to methylate histone 3 lysine 9 (H3K9me), 
generally associated with repression of gene expression. Endogenously, G9a is 
known to closely associate with GLP/EHMT1 and functions as an heteromeric 
complex (Dillon et al., 2005; Tachibana et al., 2005). G9a transfers a methyl group 
from S-adenosyl-l- methionine to ε- amino group of the substrate lysine residue 
causing mono and di methylation (H3K9me1 and H3K9me2). 
 
Figure 1.8 Schematic representation of domain structure of G9a. Adapted from 
(Shankar et al., 2013).  G9a contains a nuclear localization signal (NLS) and 
cysteine and glutamic acid rich region at N terminus. It has Ankyrin repeat (ANK) 






Apart from histones, G9a is also known to methylate non histone substrates 
including WIZ, ACINUS, HDAC and MYOD. Methylation of these factors by G9a 
generally associates with their transcriptional repression (Rathert et al., 2008; 
Shankar et al., 2013). 
G9a is expressed in most of the tissues including fetal liver, bone marrow, spleen 
and skeletal muscles (Brown et al., 2001; Ling et al., 2012a; Shankar et al., 2013). 
Loss of G9a in mice results in early embryonic lethality between embryonic days 
at E9.5-E12. G9a-/- embryos show severe growth defects and increased apoptotic 
cells. G9a-/- embryonic stem cells display growth defects when induced to 
differentiate indicating the necessity of G9a during development and differentiation 
(Tachibana et al., 2002). More recently using G9a conditional knockout mice, G9a 
was found to inhibit adipogenic differentiation by mediating repressive H3K9me2 
marks on promoters of PPARγ resulting in repression of its expression (Wang et 
al., 2013). G9a does not only mediates H3K9me, but is also capable of bringing 
about DNA methylation through its interaction with DNA methyltransferase 
DNMTs (Chin et al., 2007). For instance, LSH, a chromatin remodeling enzyme, 
recruits G9a to mediate DNA methylation and to silence genes involved in 
commitment and differentiation (Myant et al., 2011).   
Our lab has been interested in understanding the role of G9a during muscle 
differentiation. Studies from our lab have shown that G9a is expressed in skeletal 
muscle and its expression declines during muscle differentiation (Ling et al., 
2012a). G9a, when over expressed in myoblasts, inhibits myogenic differentiation 
through its ability to mediate repressive H3K9me2 on the promoter of myogenin.  
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Additionally G9a methylate MyoD and inhibits its ability to transcribe MyoD target 
genes required for differentiation (Ling et al., 2012b). G9a does not have the ability 
to directly bind to DNA. Sharp1 and MSX1 transcription factors are shown to be 
involved in recruiting G9a to the muscle promoters (Ling et al., 2012a; Wang and 
Abate-Shen, 2012).  
1.9 Activator function of G9a 
 
Although G9a is widely regarded as repressor of transcription, emerging evidence 
suggests a positive role for G9a as activator of gene expression which is 
independent of its methyltransferase activity (Bittencourt et al., 2012; Chaturvedi 
et al., 2009).  It appears that repressor or activator function of G9a depends on its 
association with either repressor or activator complex (Shankar et al., 2013). In 
adult erythroid cells, G9a is shown to suppress the embryonic β globin gene while 
it also functions as an activator for adult β globin gene expression. Association of 
G9a with Jarid1 leads to repression of embryonic globin Ey gene expression 
whereas G9a association with Mediator leads to activation of adult β globin β-maj 
gene (Chaturvedi et al., 2009, 2012). G9a is recruited by ligand activated 
glucocorticoid receptor at the glucocorticoid receptor binding sites and functions as 
activator of gene expression. G9a in cooperation with GRIP1, CARM1 and p300 
acts as a coactivator for nuclear receptors in a methyltransferase independent 
manner (Lee et al., 2006). Runx2 recruits G9a to the promoters of a subset of cancer 
related genes such as MMP9, CSF2 and SDF1 and activate their expression which 
does not require G9a methyltransferase activity (Purcell et al., 2012). From these 
studies it is clear that the role of G9a as co-activator does not require its 
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methyltransferase activity, and the function of G9a as repressor or activator might 
entirely depend upon its interacting partners (Shankar et al., 2013) (Fig 1.9). 
 
Figure 1.9 Schematic representation of G9a functioning as transcriptional 
repressor and activator (Shankar et al., 2013).  G9a associates with co-repressor 
and co-activator complex leading inhibition (p21, Myogenin Embryonic β-globin) 
or activation of gene expression (GR target genes adult β globin).  Repressor 
function of G9a requires SET domain whereas activator function of G9a is 
independent of SET domain.  
 
1.10 Role of G9a in cellular proliferation  
 
Emerging evidence suggest a role for G9a in regulating proliferation of cells. p21, 
a tumor suppressor gene and a cyclin dependent kinase (Cdk) inhibitor, controls the 
Cyclin-CDK complex at G1 phase. It is a key cell cycle checkpoint regulator and 
several studies have demonstrated the role of G9a in regulating p21 expression. 
Several transcriptional factors recruit G9a to regulate p21 gene expression. For 
instance, CDP/cut a transcription factor involved in proliferation, differentiation 
and many cellular processes, is shown to interact with G9a in vivo and in vitro.  p21 
expression is repressed by CDP/cut and this transcriptional repression function of 
CDP/cut is due to its association with G9a and the methyltransferase activity of 
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G9a (Nishio and Walsh, 2004). Similarly UHRF1, (ubiquitin-like containing PHD 
and RING finger domains 1), a protein associated with cell proliferation and 
epigenetic regulation, interacts with G9a and is found to be co-localized in nucleus 
in a cell cycle dependent manner. UHRF1 recruits G9a to the promoter of p21 to 
repress its expression (Kim et al., 2009). Gif1, growth factor dependent 1, a 
transcriptional regulator oncoprotein, is also shown to recruit G9a to modify its 
target genes. Gif1 associates with HDAC1 and G9a on p21 promoter resulting in 
its repression (Duan et al., 2005). Studies have shown that BIX-01294, a potent 
inhibitor of G9a activity, reduces the proliferation in ovine fetal pulmonary arterial 
smooth muscle cells, suggesting the importance of G9a in proliferation. BIX-01294 
treatment did not only induced G1 cell cycle arrest characterized by higher p21 
expression, but also inhibited migration, contractility and altered global 
methylation levels (Yang et al., 2012). 
Several studies have highlighted the role for G9a during replication. Gene 
expression analysis on G9a conditional knockout mouse ESCs found that 
significant numbers of late replicating genes including Magea1 and Dub1a were 
repressed by G9a, and its loss led to reduced H3K9me2 and de-repression of these 
genes that were found at the nuclear periphery. This suggest that G9a might be 
important to create a facultative heterochromatin at the nuclear periphery (Yokochi 
et al., 2009). During replication DNMT1, DNA methyltransferase 1, interacts with 
G9a and is co-localized in nucleus. DNMT1 forms a complex with G9a at 
replication foci, directing DNA and H3K9 methylation during cell division, 
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suggesting that both molecules work together to restore heterochromatin at 
replication fork during S phase (Estève et al., 2006).   
Despite its vital requirement at the early embryonic developmental stages, and for 
proliferation of cells, a few studies have looked into role of G9a in regulating 
quiescence (G0 phase). Quiescence requires active repressive settings at the 
chromatin level to keep a check on proliferation and differentiation specific genes 
to maintain the G0 state.  G9a was shown to be in complex with E2F6 (E2F6.com1) 
and other Polycomb group proteins to form a repressor complex on E2F responsive 
promoters in G0 phase (Ogawa et al., 2002). G9a mediated chromatin silencing has 
also been implicated in establishment of latent HIV 1 provirus. Viral latency 
requires modifications of the integrated viral gene to maintain quiescence.  G9a has 
been shown to repress HIV 1 gene expression and is responsible for transcriptional 
quiescence of latent HIV 1 provirus by mediating H3K9me2 on HIV 1 long 
terminal repeat promoter, which is dependent on the methyltransferase activity of 





1.11 Role of G9a in cancer 
 
High G9a expression has been correlated with several cancers including prostate, 
lung and hepatocellular carcinoma (Shankar et al., 2013).  G9a has been shown to 
repress Ep-CAM in lung cancer cells leading to higher migration and invasion 
(Chen et al., 2010) and suppresses Runx3 expression in gastric cancer cells in a 
methyltansferase activity dependent manner (Chen et al., 2006). G9a suppresses 
p53 activity by methylating its lysine residue 373, suggesting another level of 
control over p21 expression by G9a and indicating that G9a could be a potential 
inhibitory target in the treatment for cancer (Huang et al., 2010).   
Overall, the above mentioned studies indicate that G9a has an important role to play 
in oncogenesis. High G9a expression is correlated with cancer progression and poor 
prognosis in cancer patients. G9a has been functionally linked to proliferation, 
cancer invasiveness and cancer progression. However, the mechanisms behind G9a 
regulation of cell cycle and proliferation are not clear.  Although G9a association 
with few cell cycle regulators have been studied, finding the targets of G9a at global 
level is crucial for better understanding of its function. This might provide critical 
information on cell cycle regulation by G9a and also help us to gain more insights 








Myogenic differentiation requires irreversible cell cycle exit. Previous studies from 
our lab have shown that G9a is expressed in proliferating myoblast and its 
expression declines during differentiation. Moreover, over expression of G9a was 
found to inhibit myogenic differentiation (Ling et al., 2012a, 2012b). 
Mechanistically, G9a was found to be complex with MyoD in myoblasts and 
repress its transcriptional activity and consequently expression of its downstream 
targets. However, whether G9a has an impact on proliferation of myoblasts, and 
their ability to irreversibly exit the cell cycle has not been addressed. Moreover, 
genome wide targets of G9a in skeletal muscle cells have not been identified 
1.12.2 Objectives 
 
1. To identify genome wide targets of G9a in skeletal muscle cells 
2. To examine whether G9a has a role in regulating proliferation and cell cycle 
exit during myoblast differentiation 
3. To investigate the mechanisms by which G9a regulates proliferation and 
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2. Materials and methods 
 
 2.1 Mice 
 
G9afl/fl mice were kindly provided by Alexander Tarakhovsky. G9afl/fl mice were 
crossed with tamoxifen inducible Pax7Cre-ERT2 Cre mice (Jackson Laboratory). All 
mice used for experiments carried the genotype G9afl/fl; Pax7Cre ERT2/+. To induce 
Cre recombinase activity in Pax7+ muscle satellite cells, tamoxifen (1mg/10g body 
weight) was injected intraperitoneally into 1 month old G9afl/fl;Pax7Cre ERT2/+  mice 
for 5 consecutive days. Control mice with same genotype were injected with vehicle 
(corn oil). 10 days after the last injection, mice were euthanized using CO2 
asphyxiation and skeletal muscle from hind limbs were harvested for myoblast 
isolation. Genotyping was done using DNA from tail biopsies. Tail was digested in 
DNA digestion buffer (50 mM Tris-HCl pH 8.0, 100 mM EDTA pH 8.0, 100 mM 
NaCl, 1% SDS) with proteinase K (0.3mg/ml) at 550C overnight. DNA was isolated 
using phenol-chloroform extraction method. Genotype was confirmed by PCR with 
following conditions (940C- 3min, 940C-20sec, 600C-20sec, 720C-30sec, 35 cycles, 
720C-10min). Primers sequences are provided in table III.  All mice were housed 
in sterile well ventilated cages under 12 hour light dark cycle in an animal facility. 
All mice experiments were performed in accordance to protocols approved by 





2.2 Primary myoblast isolation and culture 
 
Primary myoblasts were isolated from hind limb muscles both from control and 
tamoxifen injected mice. In addition, for knockdown studies, primary myoblasts 
were isolated from hind limb muscle from wild type C57BL/6 mice. Mice were 
euthanized using carbon dioxide asphyxiation.  Limbs were disinfected with 70% 
alcohol and using sterile scissors and forceps, outer skin was removed.  Quadriceps 
and tibialis anterior (TA) muscle were dissected away from bone and was collected 
in sterile PBS with 1X penicillin-streptomycin. All procedures were carried out in 
sterile conditions in a tissue culture hood. Muscle tissue was minced to slurry with 
blade in a petri dish. 500ul of collagenase solution containing 1.5U/ml collagenase 
(Sigma), 2.5U/ml dispase (Roche) and 2.5mM CaCl2 was added on to the slurry 
and minced for few minutes. Tissue slurry was pipetted out into falcon tube and 
incubated at 370C for 15 - 20 minutes. Every 5 min the tissue slurry was triturated 
with pipette to break the clumps. Slurry was diluted with plain F10 media (Gibco) 
and filtered through the 100um cell strainer. Next, the slurry in media was 
centrifuged at 1,200rpm for 5 min to pellet the cells. The pellet was suspended in 
F10 media supplemented with 20% FBS and 5ng/ml basic fibroblast growth factor 
(bFGF), and plated on to collagen coated petri dishes (tissue culture petri dishes 
were coated with 0.01% collagen from calf skin (Sigma) overnight and dried). Cells 
were incubated at 370C with 5% CO2 and media was changed after 48hr. For 
myoblast enrichment, heterogeneous population of cells were trypsinized and pre-
plated onto culture dish for 15-30 minutes to remove strongly adherent fibroblasts. 
Unattached floating cells were collected and plated onto new collagen coated dish. 
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Pure myoblast population was confirmed by staining cells with Pax7. More than 
95% of cells stained positive for Pax7 and were used for further experiments.    
2.3 Cell lines and culture conditions 
 
2.3.1 C2C12 (mouse myoblast cell line)  
 
C2C12 mouse myoblast cells were cultured in growth medium comprising of 
Dulbecco’s Modified Eagle Medium (DMEM) high glucose (Sigma) supplemented 
with 20% fetal bovine serum (FBS) (Hyclone) and 1X penicillin-streptomycin 
(Gibco). For proliferation assays, C2C12 cells were cultured at 70% confluence and 
for differentiation assay, 80-90% confluent cells were provided with DMEM high 
glucose supplemented with 2% horse serum (Gibco) for different time points of 12, 
24 and 36 hrs. Differentiation medium was changed every day. 
2.3.2 Phoenix cells 
 
Phoenix cells were cultured in DMEM high glucose supplemented with 10% FBS 
with penicillin-streptomycin (1X). Growth medium was changed every alternate 
day. All the cells were incubated at 370C with 5% CO2 in a humidified incubator. 
2.3.3 Cryopreservation of cells 
 
Cells were trypsinized and pelleted using centrifugation. Pelleted cells were 
suspended in freezing medium (90% FBS with 10% dimethylsulfoxide (DMSO). 
Freezing mixture was aliquoted into cryovials and stored at -800C in an insulated 
box. After 24hrs, vials were transferred to liquid nitrogen for long term storage.  
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2.4 G0 synchronization (quiescence)  
 
Quiescence was induced in C2C12 cells using suspension culture method 
(Milasincic et al., 1996). Adherent proliferating C2C12 cells were washed with 
PBS, trypsinized and cell count was performed. Cell suspension was prepared with 
1X105 cells per ml along with 1.4% (final) methylcellulose (Sigma) medium 
containing 20% FBS, 10mM HEPES pH 7.4 (Sigma), 1X penicillin-streptomycin. 
Cell suspension was cultured in 50ml polypropylene falcon tubes with loosened cap 
and was incubated at 370C for 48hrs.  Cells were harvested by diluting the cell 
suspension with PBS, washing it 3 times. Pelleted cells were then suspended in 
C2C12 growth medium and plated on to petri dish or were taken for further 
analysis. 
2.5 Plasmids   
 
pBabe and pBabe-G9a retroviral vectors, Flag-G9a (1,001aa), EGFP-G9a were 
kindly provided by Dr. Martin J Walsh (Mt Sinai School of Medicine New York 
NY 10029). Flag-P/CAF was provided by Dr. Yoshihiro Nakatani (NIH, USA). For 
luciferase reporter assay, a firefly luciferase reporter construct pD1luc containing 
E2F1 binding site in CyclinD1 promoter was provided by Dr. Michael Strauss.  
Site directed mutagenesis: The E2F1 binding site in pD1luc was mutated 
(TTTGGCGC to TTTGGATGC) using the QuickChangeTM site-directed 
mutagenesis kit (Agilent). The mutants were generated from pD1luc using the 
primers listed in the table III. The cDNA was sequenced to confirm the presence of 
directed mutations. Flag-p21 and Flag-Rb1 was constructed as below.  
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2.5.1 Cloning and transformation 
 
Mouse p21 and Rb1 cDNA was separately cloned into pCMV 3X Flag (10) vector 
flanking restriction sites HindIII and BamHI. Ligation was carried out using T4 
DNA ligase (Thermo scientific) and transformation was carried out using 
competent cells DH5α. Ligated DNA and competent cells were mixed and 
incubated on ice for 30min. Cells were subjected to heat shock at 420C for 90 
seconds and cooled on ice for 5 minutes. Cells were recovered in 1ml broth at 370 
C for 1hr. Cells were pelleted by centrifugation at 6,000rpm for 5 min and then 
inoculated on to the bacterial culture plates with ampicillin overnight at 370C.  
Single clones were isolated and inoculated into 10ml of broth and incubated 
overnight. Plasmid extraction was carried out using Promega Miniprep kit as per 
manufacturer’s protocol. 
Plasmid midi preparation was carried out using Qiagen kit. In brief, 10ul of 
bacterial glycerol stock was inoculated into 2ml broth as starter culture for 
overnight with suitable antibiotics. Next day morning, culture were stored at 40C, 
later in the evening again 1ml of the culture was inoculated into 200ml broth 
containing antibiotics. Flasks were incubated at 370C for overnight in an orbital 
shaker. Bacterial cells were pelleted at 6,000rpm for 15 min, resuspended in P1 
buffer, lysed in P2 buffer and mixed with P3 buffer. Bacterial lysate clearing step 
was carried out by centrifuging cells at 20,000g for 30 min at 40C. Plasmid was 
washed, eluted using Qiagen tip columns as per the manufacturer’s instructions.  
DNA was quantified using Nanodrop.  
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2.6 DNA Transfections 
 
2.6.1 Retroviral transduction 
 
Phoenix packaging cells were used to produce retroviral supernatant. Briefly, 1.5 
million cells were seeded in a 10cm dish. Next day, transfection was carried out 
with 30ug of pBabe and pBabe-G9a plasmid separately using CaPO4 transfection 
kit (Invitrogen) according to manufacturer’s instructions. Briefly, 40ul of 2M CaCl2 
was mixed with 30ug of DNA in an Eppendorf tube. The volume was adjusted to 
300ul with sterile water. While vortexing, 300ul of 2X HBS was added slowly, 
bubbling air through to the DNA mixture. The resulting DNA complex was 
incubated for 15min at room temperature. The precipitate was added onto the 
Phoenix cells with 10ml of media and incubated for 24hrs. Later, culture medium 
was changed to C2C12 growth medium for virus collection from the transfected 
Phoenix cells. Every 24hrs, media containing virus was collected and filtered using 
0.45um syringe filter and stored at -800C.  
 G9a over expressing C2C12 stable cell line was generated by transducing C2C12 
cells with virus generated from pBabe vector alone or pBabe-G9a. Infection was 
carried out using C2C12 growth medium containing the virus, for which 8ug/ml 
polybrene (Sigma) was added and incubated for 8hrs at 370C. Media was changed 
with normal C2C12 growth media after 8hrs of infection. Cells were allowed to 




2.6.2 Transient transfections 
 
Transient transfections were carried out using Lipofectamine and Plus reagent 
(Invitrogen). A day before transfection, cells were trypsinized and plated at desired 
density so that on the day of the transfection, the cells would reach 40% confluence.  
Briefly, DNA (for instance 2ug for a 10cm dish) was mixed with 250ul of DMEM 
without FBS and antibiotics in a 1.5ml Eppendorf tube. 2ul Plus reagent/µg of DNA 
was added to the DNA mix and incubated for 5 min. In a separate tube, 
Lipofectamine (3ul of Lipofectamine for 1µg DNA) was mixed with 250ul plain 
DMEM and incubated for 5 minutes.  DMEM-Lipofectamine mixture was added 
to the mixture containing the DNA-Plus complex to a final volume of 500ul and 
incubated for 20 minutes at room temperature. DNA-Lipofectamine transfection 
mixture was added on to the cells for which medium had been changed to DMEM, 
and incubated for 3-4hrs at 370C in CO2 incubator. After 4hrs, transfection media 
was removed and cells were fed with growth media.   
2.6.3 siRNA transfection  
 
Knockdown experiments were performed using 100nm scrambled siRNA (on-
target plus control pool) or siRNA specific for G9a (siG9a; on-target plus smart 
pool, Mouse BAT8; accession number: NM_147151; NM_145830) from 
Dharmacon using Lipofectamine RNAiMax (Invitrogen) according to 
manufacturer’s instruction. Sequences for siRNA are provided in the table (Table 
I). 5μl (100nm) of each siRNA was mixed separately with 100μl plain DMEM 
medium. 3.5μl of RNAiMax Lipofectamine was added to DMEM in a separate tube 
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and incubated for 5 min. Both siRNA mix and RNAiMax were mixed and incubated 
for 20 minutes and later, the complex was added to the cells in DMEM. Transfection 
was carried out for 3-4hrs and later cells were fed with growth medium. For C2C12, 
cells were taken for experiments after 48hrs knockdown. For primary myoblasts, 
cells were taken for analysis after 72hr of knockdown.  
 
Table I: siRNA sequences  
 
Smart pool siRNA Sequences 
Non-targeting siRNA -1 UGGUUUACAUGUCGACUAA 
Non-targeting siRNA -2 
 
UGGUUUACAUGUUGUGUGA 




























2.7 Luciferase reporter assay 
 
Luciferase reporter assay was performed using the Dual Luciferase Reporter 
System (Promega). pBabe and pBabe-G9a cells were transfected with 200ng of 
cyclinD1 reporter construct in a 24-well plate. Transfection was carried out in 
triplicates with Lipofectamine Plus. 2ng of Renilla reporter construct was also 
transfected as a normalization control. 24hrs after transfection, cells were lysed for 
30 min using 1X passive lysis buffer provided in the kit. 100 μl of LAR II enzyme 
was added to 20μl of protein in a 96 well plate to measure the firefly luciferase 
signal and later, 100μl of stop and glow buffer was added to measure the Renilla 
activity. Luminescence reading was carried out using Varioskan plate reader using 
SkanIt software.   
2.8 RNA isolation and Microarray 
  
Total RNA was extracted from proliferating C2C12 cells (Day0) and differentiated 
(Day1) cells transfected with scrambled siRNA or siG9a. Briefly, cells were lysed 
in 500ul Trizol (Invitrogen) per million cells in 1.5ml Eppendorf tubes and 
vortexed. Chloroform was added to separate the phases and RNA was precipitated 
from the aqueous phase using isopropanol. RNA pellet was washed using 70% 
alcohol, and pellet was air dried and dissolved in nuclease free water. RNA was 
cleaned up using RNeasy MiniElute Cleanup Kit (Qiagen), was then quantified 
using Nanodrop. For microarray analysis, RNA quality was checked using 
Bioanalyzer (Agilent technologies).   
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Microarray was performed with RNA from two biological replicates. RNA was 
reverse transcribed and cRNA was synthesized using Total prep RNA amplification 
kit (Amibion). cRNA was labelled and subsequently hybridized to Illumina mouse 
WG-6 v2.0 array (Illumina). Partek Genomics Suite version 6.5 0 (Partek Inc., MO, 
USA) was used to perform gene expression analysis. Analysis of Variance 
(ANOVA) was applied on the data set from two samples and differentially 
expressed gene list was generated using p value < 0.05 with 1.3 fold change cut off. 
2.9 Quantitative real time PCR (q-RTPCR) 
 
To validate the results from the microarray analysis, quantitative real time PCR was 
performed on a few selected genes. Briefly, 1 µg of RNA was used to convert into 
cDNA using first strand cDNA synthesis kit (Invitrogen). cDNA was prepared 
according the manufacturer’s protocol. Quantitative real time PCR was carried out 
using Light cycler 480 SYBR green I master (Roche).  Reactions were done in 
triplicates, loaded onto the 384 well plate and PCR was performed in the Light 
cycler 480 II machine (Roche). ΔCT and 2^-ΔCT method was used to analyze the 
relative expression from the CT values.  Primers used in the study are mentioned in 




2.10 Chromatin immunoprecipitation (ChIP) 
 
Chromatin immunoprecipitation was carried out using Millipore ChIP kit. 
Chromatin was cross-linked to protein by adding formaldehyde (Sigma) (1% final 
concentration in media) for 10 min at 370C.  Media was removed and cells were 
washed twice with cold 1X PBS buffer. Cells were removed/scraped out into a 
conical tube and centrifuged for 5 minutes at 2,000rpm, 40C. 
Cells were lysed with 200µl SDS lysis buffer (with Protease Inhibitors) per 1X106 
cells.  Lysate was incubated on ice for 10–30 min (depending on cell type) - for 
myoblasts, 10 min on ice, for day 1 myocytes, 20 min on ice. Cell lysate was 
sonicated using Bioruptor (Diagenode) with the below settings. 1X106 cells per 
200ul lysis buffer was maintained and samples were kept on ice throughout.  
For day 0 myoblasts the following setting was used: Bioruptor power setting HIGH; 
30s ON / 30s OFF; 10 cycles. For day 1 myocytes: power setting HIGH; 30s ON/ 
30 s OFF; 12 cycles. For day 2 myotubes: power setting HIGH; 30s ON/ 30 s OFF; 
14 cycles. Sonicated samples were centrifuged at 40C for 10 minutes and 
supernatant was collected.   
ChIP was carried out according to kit protocol (Millipore) using antibodies 
mentioned in the table (Table II). Beads washing was carried out using wash buffers 
as per kit protocol. Reverse cross linking was performed at 650C overnight with 5M 





qRT-PCR was performed as explained previously.  DNA isolated from 10% input 
was used as control.  Relative enrichment was calculated using 2^-ΔCT method.  
Table II: Antibodies used for ChIP 
 
ANTIBODY COMPANY DILUTION 
Anti H3K9me2 Millipore 2ug 
Anti-G9a Abcam 8ul 
Anti-E2F1 Abcam 2ug 
Anti H3K9ac Millipore 2ug 









Sequence 5’ to 3’ Annealing 
temperature 
Mouse Gapdh F- ATCAACCGGGAAGCCCATCAC 
R -CCTTTTGGCTCCACCCTTCA 
60 
Mouse Cyclin E F-TGTCCTCGCTGCTTCTGCTTTGTATCAT 
R -GGCTTTCTTTGCTTGGGCTTTGTCC 
60 
Mouse Cyclin D1 F-AAGTGCGTGCAGAAGGAGATTGTG 
R -TCGGGCCGGATAGAGTTGTCAGT 
60 
Mouse p21 F-GCAGCCGAGAGGTGTGAGC 
R-ACGGGACCGAAGAGACAACG 
60 








Mouse Rb1 F-ACGCTGCCCAGGAGACCTTT 
R-AGGGCTTCGAGGAATGTGAGGT 
60 
Primers for ChIP qRT-PCR 
Mouse Cyclin D1 F-GAGAGCTTAGGGCTCGTCTG 
R-TGGGTGCGTTTCCGAGTAC 
60 
Mouse p21 F-CCCCGCATGCCCAGTTTATGG 
R-GGTCTGTCCCTGACCAACTGTG 
60 
Mouse Rb1 F-AGCCCAGGCTTGCAACCTACCC 
R-CCGCGTCACATAGCAGGTCCC 
60 
Mouse Dhfr F-GCCTAAGCTGCGCAAGTGGT 
R-GTCTCCGTTCTTGCCAATCC 
60 
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2.11 G9a methyltransferase activity inhibition  
 
G9a methyltransferase activity was blocked using UNC0638 compound (Sigma) 
known to selectively inhibit G9a methyltransferase activity (Vedadi et al., 2011). 
UNC0638 effect on myoblasts differentiation was checked using different 
concentrations and a concentration of 0.25µM was found to be optimal. As a 
control, cells were treated with DMSO. Treatment was carried out for at least 36hr 
before harvesting the cells for further analysis. For differentiation assay, cells were 
pretreated for 24hrs in growth medium and then treatment was continued in the 




2.12 BrdU incorporation assay 
 
Proliferation of cells was measured by pulsing cells with 10mM BrdU for 30 
minutes. Cells were fixed with 70% alcohol with 50mM glycine at -200C for 20 
minutes. BrdU staining was carried out using BrdU staining kit according to 
manufacturer’s protocol (Roche). Cells were incubated for 1hr at room temperature 
with anti-BrdU antibody (1:100) diluted in incubation buffer provided in the kit. 
After 3 washes with PBS, secondary antibody (1:100) labelled with FITC was 
added for 1hr at room temperature. Cells were again rinsed with PBS 3 times, nuclei 
was counter stained with DAPI and cells were mounted with mounting agent 
(Vectashield) and visualized using Olympus microscope (DP72). BrdU positive 
cells were quantified by ratio of BrdU positive cells to the total number of DAPI 




2.13 Flow cytometry analysis 
 
Cells were trypsinized and collected by centrifugation. Cell pellet was washed once 
using PBS and centrifuged again at 1,200rpm for 3 minutes.  Cells were fixed with 
70% alcohol while vortexing to avoid clumping of cells. Cells with alcohol was 
stored at -200C for at least 24hr. Later, cells were washed with PBS and centrifuged 
at 1,200rpm for 5 min. Cells were stained with 300µl propidium iodide (Sigma) 
mix (10µg/ml propidium iodide solution with RNAase A) for at least 30 minutes at 
room temperature. Cells were strained using 40um filters to avoid clumps and run 
through BD FACS machine.  At least 10,000 cells were acquired during the run.  
2.14 Immunofluorescence imaging 
 
Cells were cultured on sterile cover slips placed in 6-well dishes. Cells were fixed 
with 4% paraformaldehyde (Sigma) for 20 minutes at room temperature. Cells were 
gently rinsed with PBS for 3 times. Fixed cells were blocked and permeabilized 
using PBS containing 10% horse serum (Gibco) and 0.1% tritonX 100 (Biorad) for 
1hr at room temperature. Cells were then incubated with antibody in the blocking 
solution (PBS with 10% horse serum) at desired concentration at 40C for overnight. 
Next day, cells were gently rinsed 3 times with PBS, and incubated with secondary 
antibody tagged with fluorophore (Alexa fluor 488 or Alexa fluor 565) at 1:250 
dilution. Cells were incubated for 1hr at room temperature. Later, cells were again 
rinsed with PBS and DNA was counter stained with DAPI, and mounted using 




Table IV: Antibodies used for Immunofluorescence staining 
 
ANTIBODY COMPANY DILUTION 
Anti- Myosin heavy 
chain (My32) 
Sigma 1:300 
PAX7 DSHB 1:10 
Alexa fluor 488 goat 
anti rabbit 
Invitrogen 1:250 




For staining with anti-myosin heavy chain antibody (MY32; Sigma), incubation 
were done for 1hr at room temperature, after which nucleus was counterstained 
with mounting agent containing DAPI (Vectashield). Myogenic index was 
calculated by quantifying the ratio of total nuclei within myotubes to total nuclei. 
At least 500 nuclei was counted.   
2.15 SDS PAGE and Western blotting 
 
Cells were lysed in NP40 buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 5mM 
EDTA, 15mM MgCl2, 1% NP-40, 0.75% Sodium deoxycholate, 1mM DTT) with 
1X protease inhibitor (Roche). Protein quantification was carried out using 
Bradford reagent (Biorad). 1 part of 5X Bradford reagent was diluted with 4 parts 
of MilliQ water to get 1X reagent. 1µl of protein was added to Bradford reagent in 
a cuvette and mixed, incubated for 3-5 min before taking the absorbance at 595nm 
using spectrophotometer. Quantified protein was denatured using SDS loading dye 
at 980C for 5 minutes.  Protein was run on SDS polyacrylamide gels at 90 Volts.  
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Protein was transferred (wet transfer at 100V for 2hr) onto nitrocellulose membrane 
(Amershan hybond ECL). Transfer was carried out in cold conditions using ice 
packets.  
Membrane was blocked with 5% skimmed milk (blotto, Santa Cruz) in 0.1% Tween 
in PBS (PBST) for 1hr. Primary antibodies were diluted in 5% milk and incubated 
either 1hr room temperature or overnight at 40C depending on the antibody. 
Membrane was washed 3 times with PBST 5 minutes each to remove the unbound 
antibody. Blots were incubated with horse radish peroxidase conjugated secondary 
antibody for 1hr at room temperature and again washed 3 times with PBST. Bands 
were visualized either using detection reagents from Amershan ECL detection 




Table V: Antibodies used for western blotting 
 
ANTIBODY COMPANY DILUTION 
Rabbit polyclonal anti-G9a Cell signaling 1:300 
Rabbit polyclonal anti-p21 Santa Cruz 1:500 
Mouse monoclonal anti-Rb1 BD bioscience 1:500 
Mouse monoclonal anti-Rb1 Santa Cruz 1:500 





Rabbit polyclonal anti-myogenin Santa Cruz 1:500 
Rabbit polyclonal anti-Cyclin A Santa Cruz 1:100 
Rabbit polyclonal anti-CyclinD1 Santa Cruz 1:500 
Anti-troponin-T Sigma 1:1000 
Anti-βactin Sigma 1:10000 
Anti-Flag Sigma 1:1000 
 
2.16 Co-immunoprecipitation (Co-IP) 
 
For endogenous Co-IP, nuclear extracts were prepared from proliferating C2C12 
myoblasts by following modified Dignam’s protocol. Briefly, 100 million cells 
were trypsinized and washed twice with ice cold PBS. Cell pellet was incubated 
not more than 2 minutes by resuspending gently in 10ml of ice cold homogenization 
buffer with DTT and protease inhibitors (For the buffers recipe, see below). Cell 
suspension was slowly layered onto cold sucrose pad (8-10ml). Cells were 
centrifuged at 900rpm for 10 minutes at 40 C with no brakes. Supernatant was 
aspirated and nuclei at the bottom were washed with wash buffer (10ml) before 
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centrifugation at 14,000 rpm at 40C for 45 minutes to get rid of all cytoplasmic 
residues. Intact nuclei were observed under microscope with trypan blue. Nuclei 
pellet was resuspended in 1 packed volume of cold buffer C 0mM.  Next, 2 packed 
volume of cold buffer C 840mM was added drop by drop while vortexing slowly. 
Every 5 drops, nuclei was incubated on ice. Nuclei were further lysed by 15 strokes 
with dounce homogenizer (Pestle B). Lysed nuclei were observed with trypan blue 
under microscope. The homogenate was gently stirred with a magnetic bar for half 
an hour at 40C and then centrifuged at 14,000rpm for 30 minutes at 40C. 
Supernatant was carefully recovered and diluted in 2 volumes of buffer D (for e.g. 
for 1ml supernatant 2ml buffer D).  Pellet containing DNA and histone were left 
behind.   
For endogenous co-immunoprecipitation, at least 1mg of protein was used to pull 
down with desired antibody.  Protein lysate was pre-cleared using 30ul of protein 
A/G agarose beads (Santa Cruz) for 45minutes. Lysate was incubated with desired 
antibodies for overnight at 40C under rotation. Protein A/G agarose beads was then 
added (30ul) the following morning to the lysate for 2hr and kept for rotation at 
40C. Beads were pelleted by centrifugation at low speed (2,000rpm) at 40C and 
washed with NP40 buffer with protease inhibitors for 3 washes lasting 5 minutes 
each. After final wash, sample loading dye (10ul) was added to the beads, heated 




Table VI: Antibodies used for Co-IP 
 
ANTIBODY COMPANY CONCENTRATION 
Anti-MyoD Santa Cruz 2ug 
Anti-G9a Abcam 8ul 
Anti-E2F1 Abcam 2ug 
Anti-Flag beads Sigma 20ul 
Normal rabbit IgG Santa Cruz 2ug 
 
2.16.1 Solutions for nuclear extract 
 
Salt stock (100ml):  10ml 1M Tris-HCl, pH 7.5, 3ml 5M NaCl, 60ml 1M KCl, top 
up with water to 100ml and store at RT.  
Homogenization buffer (50ml): 5ml salt stock, 7.35ml 1M (34%) sucrose, 250ul 
20% NP40, 100ul 0.5M EDTA, 10ul 0.5M EGTA, 32.3ml water.  (Prior to use, add 
to per ml of buffer: 0.5ul 1M DTT, 1X PI)  
Sucrose pad (10ml): 1ml salt stock, 2.94ml 1ml sucrose, 5.06ml water. (Prior to 
use, add to per ml of buffer: 0.5ul 1M DTT, 1X PI) 
Wash buffer (50ml): 5ml salt stock, 100ul 0.5M EDTA, 10ul 0.5M EGTA, 40ml 
water. (Prior to use, add to per ml of buffer: 0.5ul 1M DTT, 1X PI) 
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Buffer C 0mM (9ml): 5ml 20mM HEPES pH 7.9, 25% glycerol, 0.2mM EDTA , 
1.5mM MgCl2. (Prior to use, add to per ml of buffer: 0.5ul 1M DTT, 1X PI) 
Buffer C 840mM : 20mM HEPES, pH 7.9, 25% glycerol, 0.2mM EDTA, 1.5mM 
MgCl2, 840mM KCL.  (Prior to use, add to per ml of buffer: 0.5ul 1M DTT, 1X 
PI) 
Buffer D: 20mM HEPES, pH 7.9, 20% glycerol, 0.2mM EDTA, 0.3% triton X 
100. (Prior to use, add to per ml of buffer: 0.5ul 1M DTT, 1X PI)   
 
2.17 Statistical analysis 
 
Error bars represent mean standard deviation (SD). Significance was calculated 
using student t test (two tailed paired unless specified others) with p value <0.05 





3. Results  
 
3.1 G9a expression correlates with proliferation of myoblasts 
 
In order to find out if G9a has a role in proliferation and cell cycle exit of myoblasts, 
we examined its expression in different cellular states – proliferation, irreversible 
cell cycle exit (differentiation); and reversible cell cycle exit (quiescence). RNA 
and protein was extracted from proliferating C2C12 myoblasts, differentiated 
myocytes (Day 1) and quiescent myoblasts. G9a mRNA and protein expression was 
analyzed by quantitative real time PCR and western blot respectively. G9a mRNA 
level was higher in proliferating cells compared to cell cycle exit states (Fig 
3.1A&B). Similarly, G9a protein expression was also high in myoblasts and 
declined upon differentiation and quiescence (Fig 3.1C&D). Thus G9a is expressed 
at higher levels in proliferating cells compared to cell cycle exit states, and suggest 






Figure 3.1. G9a expression decreases during myoblast cell cycle exit. (A & B) 
Relative quantification of G9a expression in proliferating myoblasts (D0), 
differentiated (Day 1) myocytes and quiescent C2C12 myoblasts (Quiescent 
progenitors) by qRT PCR. Gapdh was used to normalize the expression. (C & D) 
G9a protein level was analyzed in myoblasts (D0), differentiating myocytes (D1 & 
D2) and quiescent cells S48 (myoblasts cultured in suspension medium for 48hr) 
using western blot. β-actin was used as loading control. Error bars indicate mean ± 





3.2 Identification of genome wide targets of G9a  
 
3.2.1 Gene expression studies using microarray 
 
Previous studies from our lab have shown that G9a methylates MyoD in myoblasts 
to inhibit MyoD function. This is correlated with H3K9me2 repression marks at the 
myogenin promoter indicating that G9a functions as a negative regulator of 
myogenic differentiation (Ling et al., 2012b). While these studies established a role 
for G9a in myogenic differentiation, genome-wide targets of G9a in myoblasts have 
not been identified. 
To identify G9a target genes, we performed gene expression analysis using 
microarray with G9a knock-down myoblasts. Endogenous G9a knockdown was 
performed using siRNA specific for G9a (siG9a cells). Control cells were 
transfected with scrambled siRNA (siRNA cells). G9a knockdown was confirmed 
48hr post-transfection at protein level by western blot (Fig 3.2.1A). RNA was 
isolated from proliferating day 0 (Day 0) and differentiated day 1 (Day 1) from 
siG9a cells and siRNA cells. Two independent knockdown experiments were 
performed on two different days to achieve better reproducibility. RNA from both 
sets was reverse transcribed, labelled and hybridized to mouse WG6v2.0 array from 
Illumina.  
From the microarray analysis, we identified 311 unique genes which were 
differentially regulated by 1.3 fold with p-value <0.05. 173 genes were up regulated 
whereas 138 genes were down regulated. G9a knockdown significantly altered 
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genes involved in different cellular pathways among which cell cycle control and 
muscle differentiation pathway genes were highly enriched (Fig 3.2.1B).  
Figure 3.2.1A,B&C. Gene expression studies using microarray. (A) G9a protein 
expression was analyzed in siRNA and siG9a cells by western blot. β-actin was 
used as loading control. (B) List of G9a target genes involved in differentiation and 
cell cycle control in proliferating (Day 0) and differentiated (Day 1) cells with 
corresponding p-value.  Green indicates down regulation and red indicates up 
regulation of gene expression. (C) Activity of transcription factors altered in siG9a 
cells. (Bioinformatics for microarrays was done by Jayapal Manikandan).   
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Consistent with our previous findings which showed that G9a inhibits myogenic 
differentiation (Ling et al., 2012b), MyoD dependent genes involved in 
differentiation such myogenin were up regulated in siG9a cells.  Interestingly, in 
addition to differentiation related genes, the expression of many genes involved in 
cell cycle regulation was differentially altered. For instance, the expression of p21 
and Rb1 genes which are involved in irreversible cell cycle exit during 
differentiation was up regulated. On the other hand, E2F1 target genes involved in 
cell cycle control such as CyclinD1, CyclinE and Thymidine Kinase were down 
regulated.  
Ingenuity pathway analysis showed that the activities of MyoD and E2F1 
transcription factors were altered in G9a knockdown cells (Fig 3.2.1C). This 
indicated that G9a in addition to its impact on myogenic differentiation through 
regulation of MyoD activity, G9a may control proliferation through its association 
E2F1.  
Gene Ontology (GO) analysis for top canonical pathways and top biological 
functions showed that cell cycle regulation was altered upon G9a knockdown (Fig 
3.2.1D&E). A set of genes from gene ontology was used to create a biological 
network. The biological network indicated that cell cycle progression and muscle 
differentiation was affected in siG9a cells (Fig 3.2.1F). This suggested that G9a has 





Figure 3.2.1D&E. Gene expression studies using microarray. Ingenuity 
pathway analysis. (D) Bar chart indicating top functions altered in siG9a myoblasts. 
Cell cycle control was found to be one among the top functions altered in siG9a 
cells. (E) Bar chart indicating top canonical pathways altered in siG9a myoblasts. 
Apart from calcium signaling, Cyclins and cell cycle regulation was found to be 








Figure 3.2.1F Gene expression studies using microarray. To understand the 
biological significance of G9a target genes, Gene ontologies were used to create 
the network - Molecular function ontology (indicates function of gene at molecular 
level) and Cellular component ontology (refers to the place where gene product is 
found). (F) Biological interaction network identifying possible interactions 
between G9a target genes related to cell cycle control and differentiation. Orange 
line indicates direct interaction. Dotted line indicates indirect interaction. Grey line 




Overall, results from the global gene expression analysis indicated that G9a targets 
both MyoD and E2F1 responsive genes in myoblasts. Since G9a knockdown up 
regulated MyoD target genes, it indicated that these may be direct transcriptional 
targets of G9a. On the other hand, since E2F1 targets were down regulated, G9a 
could be directly or indirectly involved in promoting expression of these genes. 
 
3.2.2 Validation of microarray results 
 
To validate the microarray results, we performed qRT-PCR on a few selected G9a 
target genes. RNA was isolated from control and siG9a cells and converted to 
cDNA and qRT-PCR was performed. Consistent with the microarray results, siG9a 
cells showed significant up regulation of MyoD target genes p21 and Rb1 whereas 
expression of E2F1 target genes such as Cyclin D1 and Cyclin E was down 







Figure 3.2.2 Validation of microarray results. G9a targets such as (A & B) p21, 
Rb1, (C & D) CyclinD1 and CyclinE expression were analyzed by qRT-PCR in 
control and siG9a C2C12 cells. Error bars indicate mean ± SD. * indicates p-value 




3.3 G9a regulates differentiation and proliferation genes in mouse 
primary myoblasts 
 
Next, we went on to validate if G9a regulates MyoD and E2F1 target genes in 
mouse primary myoblasts. Myoblasts were isolated and cultured from hind limbs 
of wild type mice. G9a knockdown was performed using siG9a for 72hr. Scrambled 
siRNA was used as control. RNA was isolated from the cells, cDNA was 
synthesized and qRT-PCR was performed to check the G9a knockdown efficiency 
(Fig 3.3A). Consistent with the microarray data, G9a knockdown cells showed 
significant up regulation of MyoD target genes p21 and Rb1 (Fig 3.3B&C) whereas 
E2F1 target genes CyclinD1, DHFR and CyclinE were significantly down 
regulated (Fig 3.3 D, E & F).  Results from the microarray, C2C12 cells and primary 
myoblasts indicated that G9a regulate genes involved in cell cycle control and 






Figure 3.3 G9a regulates MyoD and E2F1 target genes in primary myoblasts. 
(A) G9a knockdown was analyzed by qRT-PCR in siG9a primary myoblasts. (B & 
C) p21, Rb1, (D, E & F) CyclinD1, DHFR and CyclinE expressions were analyzed 
by qRT-PCR in control and siG9a mouse primary myoblasts. Error bars indicate 





3.4 Role of G9a in proliferation  
 
3.4.1 G9a knockdown reduces proliferation of C2C12 cells  
 
To examine if G9a indeed has any role in regulating proliferation of cells, we 
performed loss of function studies by carrying out G9a knockdown in C2C12 cells 
(siG9a cells) (Fig 3.4.1A). Both control and G9a knockdown cells were pulsed with 
BrdU for 30min, fixed and stained with anti-BrdU antibody. siG9a cells showed 
significantly lesser BrdU incorporation compared to control cells. This indicated 
that G9a knockdown led to reduced proliferation of cells (Fig 3.4.1B & C).  
3.4.2 G9a knockdown reduces proliferation of primary myoblasts 
 
Next, we confirmed the above results in siG9a mouse primary myoblasts. 
Knockdown of G9a was performed in primary myoblasts and confirmed by 
qRTPCR (Fig 3.4.2A). Both control and G9a knockdown cells were pulsed with 
BrdU for 30min, fixed and stained with anti-BrdU antibody. BrdU incorporation in 
siG9a cells was lesser compared to controls, indicating reduced proliferation in 
siG9a cells (Fig 3.4.2 B&C). Further, we also performed propidium iodide staining 
and analyzed cell cycle profiles by flow cytometry. Consistent with above results, 
siG9a cells showed lesser S phase cells compared to controls (Fig 3.4.2 D&E) and 
an arrest in the G1 phase of the cell cycle. Overall, our results suggested that G9a 









Figure 3.4.2 D,E&F. G9a knockdown reduces proliferation of primary 
myoblasts. (D & E) Flow cytometry analysis of PI stained control and siG9a 
primary myoblasts. (F) Graph indicating percentage population in S phase in 
control and siG9a cells. siG9a primary myoblasts had less S phase cells compared 





3.4.3 Inhibition of G9a methyltransferase activity reduces proliferation of 
cells 
 
Since G9a knockdown led to decreased proliferation of cells, we went on to check 
if methyltransferase activity of G9a is required for its effect on proliferation. We 
treated both C2C12 cells and primary myoblasts with UNC0638 (a selective 
inhibitor of G9a methyltransferase activity) and as a control, cells were treated with 
DMSO (vehicle). Both control and UNC0638 treated cells were pulsed with BrdU 
for 30min, fixed and stained with anti-BrdU antibody. UNC0638 treated cells 
incorporated lesser BrdU compared to control, both in C2C12 cells (Fig 3.4.3A) 
and primary myoblasts (Fig 3.4.3B&C). This indicated that inhibition of G9a 
methyltransferase activity reduces proliferation of cells and G9a effect on 







3.4.4 G9a over expression increases proliferation of myoblasts 
 
Next, we performed gain of function studies to examine the role of G9a in 
proliferation. Stable G9a over expression was done in C2C12 cells using a retroviral 
vector (pBabe-G9a cells) and over expression was confirmed by western blot (Fig 
3.4.4A). To check the effect of G9a over expression on proliferation of cells, we 
performed immunofluorescence on BrdU pulsed control (pBabe) and pBabe-G9a 
cells. Both pBabe and pBabe-G9a cells were pulsed with BrdU for 30min, fixed 
and stained with BrdU antibody. G9a over expressing cells displayed higher BrdU 
positivity compared to control cells, indicating higher proliferation of pBabe-G9a 
cells (Fig 3.4.4A).  Further, we performed propidium iodide staining and subjected 
the cells to flow cytometry analysis. Consistent with the above results, we found 





3.5 Role of G9a in regulating cell cycle exit during differentiation  
 
Since G9a knockdown reduced proliferation of cells we questioned whether it 
altered cell cycle exit process during differentiation. Among the G9a target genes 
involved in cell cycle control from the array, we found a cluster of genes that were 
up regulated in siG9a cells. Interestingly, MyoD target genes p21 and Rb1, which 
are involved in irreversible cell cycle exit during differentiation were among these 
genes (Fig 3.5A).  Therefore, we looked into the role of G9a in regulating cell cycle 
exit of myoblasts during differentiation.   
 
 
Figure 3.5 Role of G9a in regulating cell cycle exit during differentiation. (A) 
List of G9a target genes involved in differentiation and cell cycle control. 






3.5.1 G9a inhibits p21 and Rb1 expression during myoblasts differentiation  
 
Since p21 and Rb1 which are required for irreversible cell cycle exit of myoblast 
are upregulated in siG9a cells, we examined if G9a alters cell cycle exit during 
differentiation. pBabe and pBabe-G9a cells were differentiated for indicated time 
points and p21 and Rb1 expression was analyzed at RNA and protein level by qRT-
PCR and western blotting. G9a over expressing cells showed reduced p21 and Rb1 
mRNA levels during differentiation (Fig 3.5.1A&C). Similarly, p21 and Rb1 
protein levels were also reduced in G9a over expressing cells during differentiation. 
Reduced p21 and Rb1 expression could result in inhibition of myoblast 
differentiation as evidenced by decreased troponin-T expression (Fig 3.5.1B&D). 
These results suggested that G9a may be involved in regulating irreversible cell 















Figure 3.5.1 A&B.  G9a inhibits p21 and Rb1 expression during 
differentiation. (A) p21 mRNA expression was analyzed in control and pBabe-
G9a cells during proliferation (D0) and day 1 differentiation (D1) condition. (B) 
pBabe and pBabe-G9a cells were differentiated for 0 to 36hrs and analyzed for p21 
and troponin-T expression by western blot. β-actin was used as internal control. 













Figure 3.5.1 C&D. G9a inhibits p21 and Rb1 expression during differentiation. 
(C) Rb1 mRNA expression was analyzed in control and pBabe-G9a cells during 
proliferation (D0) and day 1 differentiation (D1) condition. (D) pBabe and pBabe-
G9a cells were differentiated for 0 to 36hrs and analyzed for Rb1 and troponin-T 
expression by western blot. β-actin was used as internal control. Error bars indicate 
mean ± SD. * indicates p-value <0.05  
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3.5.2 G9a inhibition of p21 and Rb1 is dependent on its methyltransferase 
activity 
 
To confirm if G9a methyltransferase activity is required for cell cycle exit, we 
blocked endogenous methyltransferase activity of G9a by treating cells with 
UNC0638. Control cells were treated with DMSO (vehicle). Cells were 
differentiated for indicated time points. Western blot analysis showed increased 
p21 and Rb1 expression in UNC0638 treated cells with increased differentiation as 
evidenced by higher troponin-T expression (Fig 3.5.2 A&B). This indicated that 
G9a regulation of cell cycle exit is dependent on its methyltransferase activity.  
 
Figure 3.5.2 G9a inhibition of p21 and Rb1 is dependent on its 
methyltransferase activity. Control (DMSO treated) and UNC0638 treated 
(0.25uM) C2C12 cells were differentiated for 0 to 36hrs and protein lysates was 
analyzed for (A) p21, troponin-T or (B) Rb1 and troponin-T by western blot. β-






3.6 G9a mediates repressive H3K9me2 on MyoD target genes 
 
G9a is generally known to function as a repressor by mediating repressive 
H3K9me2 on its target genes. Since over-expression of G9a inhibited p21 and Rb1 
expression during differentiation, we checked if G9a mediates repression on both 
these promoters. Chromatin immunoprecipitation assay was performed with pBabe 
and pBabe-G9a cells under both proliferation (D0) and differentiation (D1) 
conditions.  Cells were fixed using formaldehyde and lysed using SDS buffer.  
Lysates were subjected to chromatin immunoprecipitation assay using anti-
H3K9me2 antibody. A higher level of H3K9me2 enrichment on p21 and Rb1 
promoters was seen in pBabe-G9a cells compared to control cells (Fig 3.6.A & B). 
This result confirms that G9a mediates repressive marks on p21 and Rb1 promoters 





Figure 3.6 G9a mediates repressive H3K9me2 on p21 and Rb1 promoters. (A 
& B) ChIP assay was performed in pBabe and pBabe-G9a cells under proliferation 
day 0 (D0) and differentiation day 1 (D1) conditions. H3K9me2 enrichment was 
analyzed at the p21 and Rb1 promoters. Error bars indicate mean ± SD. ** indicates 









3.7 p21 and Rb1 rescue differentiation inhibition in G9a over 
expressing cells 
 
Since G9a over expression inhibited both p21 and Rb1 required for cell cycle exit, 
we questioned if over expression of p21 or Rb1 could rescue the differentiation 
defect imposed by G9a. To this end, we performed a rescue experiment by 
transfecting p21 and Rb1 expression vector in control and pBabe-G9a cells (Fig 
3.7A).  Cells were differentiated for indicated time points and protein lysate was 
analyzed by western blot.  Consistent with our previous results (Ling et al., 2012b), 
G9a over expression inhibited differentiation.  p21 and Rb1 over expressing cells 
showed increased expression of differentiation markers compared to pBabe-G9a 
cells as evidenced by higher myogenin and troponin-T expression (Fig 3.7B).  
 We also performed immunofluorescence assay with MHC antibody which is 
expressed in differentiated myotubes. Consistent with the above results we found 
higher MHC positive myotubes in p21 and Rb1 transfected cells compared to 
pBabe-G9a cells (Fig 3.7C). Further, myogenic index was higher in p21 and Rb1 
transfected cells compared to pBabe-G9a cells (Fig 3.7D).   
Overall, all these results confirm the role of G9a in regulating irreversible cell cycle 
exit during myogenic differentiation. G9a inhibits p21 and Rb1 expression required 
for cell cycle exit and thus G9a acts as a master regulator of muscle differentiation 
program by exerting an additional layer of control over myoblast differentiation 











Figure 3.7 A&B p21 and Rb1 rescue differentiation inhibition in G9a over 
expressing cells (A) Flag-p21 and Flag-Rb1 over expression in control and G9a 
over expressing cells was checked using western blot. (B) pBabe and pBabe-G9a 
cells were differentiated for 0 to 24hrs and lysates were analyzed for myogenin and 








Figure 3.7 C&D p21 and Rb1 rescue differentiation inhibition in G9a 
overexpressing cells (C) pBabe, pBabe-G9a and pBabe-G9a cells transfected with 
p21 and Rb1 were differentiated for 0-36hrs and immunostained with myosin heavy 
chain antibody. (D) Reduction in myogenic index was observed in G9a over 
expressing cells whereas myogenic differentiation rescue was observed in cells 








3.8 Role of G9a in activating E2F1 target gene expression  
 
From the microarray results, we also found a cluster of cell cycle genes that were 
significantly down regulated upon G9a knockdown (Fig 3.8). Interestingly, most of 
these genes are E2F1 targets that are required for proliferation of cells. Although 
G9a is widely regarded as repressor of gene expression, emerging evidence 
suggests that G9a could act as an activator of gene expression as well. However, 
activator function of G9a is known to be independent of its methyltransferase 
activity (Bittencourt et al., 2012).  Since G9a promotes proliferation of cells, we 
determined whether G9a directly activates expression of these E2F1 target genes, 
or indirectly regulates their expression.  
 
Figure 3.8 Role of G9a in activating E2F1 target gene expression. (A) List of 
G9a target genes involved in differentiation and cell cycle control. Highlighted box 





3.8.1 G9a promotes E2F1 target gene expression  
 
pBabe and pBabe-G9a cells were differentiated for indicated time points and 
protein lysates were analyzed by western blot for E2F1 target gene expression. We 
found that the expression of Cyclins such as CyclinD1 and CyclinE were higher in 
G9a over expressing cells and sustained during differentiation (Fig 3.8.1A&B). 
Moreover, Rb1 was hyper phosphorylated in G9a over expressing cells which could 
in turn free E2F1. Thus in G9a over expressing cells, E2F1 would be free to 
transcribe its target genes such as cyclins required for cell proliferation. This 
suggested a positive role for G9a in promoting their expression 
 
Figure 3.8.1 G9a promote E2F1 target gene expression. (A) G9a over expression 
shown in C2C12 cells by western blot. (B) Control and G9a over expressing cells 
were differentiated for 0 to 36hr and protein lysate was analyzed to check Cyclin-
D,-E,-A, Rb1 and Troponin-T by western blot. β-actin was used as internal control. 
(Data provided by Shilpa Rani Shankar) 
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3.8.2 G9a regulation of E2F1 target genes is independent of its 
methyltransferase activity 
 
Several studies suggest that activator function of G9a is independent of its 
methyltransferase activity. Therefore, we inhibited endogenous methyltransferase 
activity of G9a and checked its effect on E2F1 target gene expression. RNA was 
isolated from mouse primary myoblasts treated with UNC0638 or DMSO, and was 
analyzed for E2F1 target gene expression. Interestingly, we found no significant 
change in the expression of E2F1 target genes upon UNC0638 treatment (Fig 
3.8.2A). However, unlike its effect on E2F1 target genes, the expression of MyoD 
target genes, p21 and Rb1, were upregulated in UNC0638 treated cells (Fig 3.8.2 
B).   
Next, we checked effect of UNC0638 treatment on CyclinD1 protein expression. 
C2C12 cells were differentiated with or without UNC0638 for indicated time points 
and protein lysates were analyzed for CyclinD1 expression. Consistent with the 
mRNA results, no change in the expression of CyclinD1 upon UNC0638 treatment 
(Fig 3.8.2C). During proliferation, hyper phosphorylated Rb1 levels remained 
unchanged, whereas consistent with earlier results, the hypo phosphorylated form 
of Rb1 increased during differentiation. These results suggest that G9a regulation 






Figure 3.8.2 G9a regulation of E2F1 target genes is independent of its 
methyltransferase activity (A) CyclinD1,DHFR and CyclinE mRNA expression 
was analyzed by qRT-PCR in control and UNC0638 treated primary myoblasts. (B) 
p21 and Rb1 expression analyzed by qRT-PCR (C) C2C12 cells were treated with 
either DMSO or UNC0638 (0.25um) and differentiated for 0-36hrs.  Protein lysate 
was analyzed for CyclinD1, pRb S780, total Rb and Troponin-T by western blot. β-
actin was used as internal control. Error bars indicate mean ± SD. *** indicates p-
value <0.001, * indicates p-value <0.05 
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3.9 G9a does not mediate H3K9me2 on E2F1 target genes  
 
Since the activator function of G9a does not involve its methyltransferase activity 
and also the fact that inhibition of G9a activity did not affect E2F1 target gene 
expression, we looked at the H3K9me2 levels at the promoters of E2F1 target genes 
in G9a over expressing cells. We performed chromatin immunoprecipitation with 
pBabe and pBabe-G9a cells and looked at G9a occupancy as well as repressive 
H3K9me2 on the promoter of CyclinD1, CyclinE (involved in cell cycle control) 
and DHFR (involved in DNA synthesis). If G9a activates E2F1 target gene 
expression, we would expect G9a occupancy on these promoters with no 
corresponding repressive H3K9me2. If G9a indirectly regulates E2F1 target genes, 
then we do not expect to see G9a occupancy on their promoters.  As expected, 
increased G9a occupancy on E2F1 target gene promoters was seen in pBabe-G9a 
cells compared to control cells. However, there was no corresponding increase in 
H3K9me2 enrichment (Fig 3.9A, B & C). In contrast, G9a occupancy was 
correlated with increased H3K9me2 enrichment on MyoD target gene promoters 
(Fig 3.9 D & E).  These results indicate that G9a may actively promote E2F1 target 









Figure 3.9 G9a does not mediate repressive H3K9me2 on E2F1 target gene 
promoters. ChIP assay was performed in pBabe and pBabe-G9a cells with G9a 
and H3K9me2 antibody. (A,B & C) G9a occupancy and corresponding H3K9me2 
enrichment was analyzed at the CyclinD1, CyclinE and DHFR promoters, and (D 
& E) at p21 and Rb1 promoters. Error bars indicate mean ± SD. ** indicates p-





3.10 Inhibition of G9a methyltransferase activity does not alter H3K9me2 on 
E2F1 target promoters 
 
To further test the methyltransferase independent role of G9a in activating E2F1 
target genes, we performed ChIP assays with cells treated with either DMSO or 
UNC0638 to block endogenous methyltransferase activity of G9a. If G9a functions 
in a methyltransferase independent manner, we would expect no change in 
H3K9me2 levels on E2F1 target gene promoters in UNC0638 treated cells, whereas 
a reduction in repression should be apparent on MyoD target gene promoters.  
Consistent with our hypothesis, UNC0638 treatment did not significantly alter 
H3K9me2 levels on CyclinD1 and DHFR promoters (Fig 3.10A & B).  However 
G9a repression on MyoD target genes p21 and Rb1 was significantly reduced upon 
UNC0638. This result indicates that G9a functions in methyltransferase 






Figure 3.10 Inhibition of G9a methyltransferase activity does not alter 
H3K9me2 on E2F1 target promoters. ChIP assays were performed in C2C12 
cells treated with either DMSO or UNC0638 with H3K9me2 antibody. (A & B) No 
significant changes in H3K9me2 enrichment on CyclinD1 and DHFR promoters (C 
& D) Significant down regulation of H3K9me2 on both the p21 and Rb1 promoters.  





3.11 G9a occupancy along with E2F1 and P/CAF correlated with increased 
H3K9ac on E2F1 target promoters 
 
Next, we examined if G9a occupancy on E2F1 target promoters is associated with 
H3K9ac (activation mark). To this end, we performed chromatin 
immunoprecipitation assay with G9a, E2F1 and P/CAF antibodies in pBabe and 
pBabe-G9a cells. Consistent with our earlier results we found G9a occupancy on 
E2F1 target genes. Furthermore, E2F1 and P/CAF occupancy was also evident on 
E2F1 target genes (Fig 3.11 A&B). Interestingly, G9a occupancy along with P/CAF 
correlated with acetylation status of E2F1 target genes. We found higher H3K9 
acetylation, a mark of transcriptional activation, on E2F1 target promoters in G9a 
over expressing cells compared to control cells. Therefore, our results suggested 
that in myoblasts, G9a could be in complex with P/CAF on E2F1 target genes and 










Figure 3.11 G9a occupancy along with E2F1 correlated with increased 
H3K9ac on E2F1 target promoters. ChIP assay was performed in control and 
G9a over expressing cells with anti G9a, anti E2F1, anti P/CAF and anti H3K9ac 
antibodies. (A & B) H3K9ac enrichment was apparent along with G9a, E2F1 and 
P/CAF occupancy on both CyclinD1 and DHFR promoters. Error bars indicate 
mean ± SD. * indicates p-value <0.05 
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3.12 G9a interacting partners in myoblasts 
 
In myoblasts, MyoD dependent genes are silenced whereas E2F1 dependent genes 
are activated. MyoD is known to be in association with repressor complex including 
Suv39h1, HDAC1 and G9a on muscle promoters leading to the block in 
differentiation. In contrast, E2F1 is associated with activator complex including 
p300 and PCAF on cell cycle gene promoters (Fig 1.7). 
3.12.1 G9a complexes with E2F1 and P/CAF in myoblasts  
 
Since we found G9a occupancy on E2F1 target gene promoters, we would expect 
G9a to be in complex along with E2F1 and P/CAF in proliferating myoblasts. To 
examine this, we performed endogenous co-immunoprecipitation assay using 
nuclear extracts from proliferating myoblasts. Co-immunoprecipitation was 
performed using anti-G9a antibody to check for its interaction with E2F1 and 
P/CAF. Rabbit IgG pulldown was used as negative control. We found G9a 
interaction with E2F1 and P/CAF (Fig 3.12.1A).  Alternatively, we over expressed 
Flag-G9a in C2C12 cells and performed Co-IP with anti-Flag antibody.  From the 
western blot analysis, we found G9a interaction with E2F1 and P/CAF (Fig 
3.12.1B).  Similarly, we also checked if G9a is present in a repressor complex with 
MyoD. We performed endogenous Co-IP with MyoD antibody. Consistent with the 
earlier studies, we found MyoD interaction with G9a and HDAC (Fig 3.12.1C).   
Taken together our results suggest that G9a is in distinct complex with E2F1 and 
MyoD in myoblasts and this could potentially explain G9a role as both an activator 




Figure 3.12.1 G9a complex with E2F1 and P/CAF in myoblasts (A) G9a 
pulldown performed with anti-G9a antibody in C2C12 nuclear extracts. IgG pull 
down was performed as control. Interaction with E2F1 and P/CAF was confirmed 
by western blot. (B) Pull down was performed with Flag beads using lysate from 
Flag-G9a over expressed C2C12 cells and interaction with E2F1 and P/CAF was 
checked by western blot. (C) Endogenous MyoD pull down was performed and 
interaction with HDAC and G9a was checked using western blot.  
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3.13 G9a over expressing cells display higher CyclinD1 promoter activity 
 
We found G9a in complex with E2F1 and P/CAF and could possibly act as activator 
of E2F1 target genes. Moreover, from our earlier results G9a overexpressing cells 
displayed hyper phosphorylated Rb1, which results in free E2F1. Therefore, we 
questioned if G9a over expressing cells display enhanced E2F1 activity. To test 
this, we performed luciferase reporter assay with cyclinD1 reporter construct. We 
transfected cyclinD1 luciferase reporter construct into control pBabe and pBabe-
G9a cells. We found that pBabe-G9a cells displayed higher cyclinD1 promoter 
activity compared to control cells (Fig 3.13A). This indicated that G9a over 
expressing cells display higher E2F1 activity. 
 
Figure 3.13A G9a overexpressing cells display higher cyclinD1 promoter 
activity and is E2F1 dependent. (A) Control pBabe and pBabe-G9a cells were 
transfected with pD1luc reporter construct. Luciferase activity was measured using 




 Next, in order to find out if the higher cyclinD1 promoter activity in pBabe-G9a 
cells is E2F1 dependent, we transfected control and G9a over expressing cells with 
either WT cyclinD1 reporter or with point mutation at E2F1 binding site (Fig 
3.13B). Interestingly, we found no significant changes in the activity of mutant 
cyclinD1 reporter (Fig 3.13B). However, consistent with our earlier results WT 
CyclinD1 promoter activity was higher in pBabe-G9a cells.  This confirms that G9a 
over expressing cells display higher E2F1 activity and this is due to free E2F1 in 
pBabe-G9a cells.    
 
 
Figure 3.13B G9a overexpressing cells display higher cyclinD1 promoter 
activity and is E2F1 dependent (B) Sequencing result from wild type pD1luc and 
point mutant at E2F1 binding site constructs.  E2F1 binding site is shown in box 
















Figure 3.13C G9a overexpressing cells display higher cyclinD1 promoter 
activity and is E2F1 dependent (C) Control pBabe and pBabe-G9a cells were 
transfected with either WT or point mutant (at E2F1 binding site) pD1luc reporter 
construct. Luciferase activity was measured using dual luciferase reporter system. 






3.14 Myoblasts from G9a knockout mice display reduced proliferation and 
decreased expression of proliferation genes 
 
Finally, to validate the physiological in vivo relevance of our findings, we isolated 
myoblasts from G9a knockout mice. Since G9a knockout is embryonically lethal 
(Tachibana et al., 2002), G9a was knocked out specifically in muscle satellite cells 
of G9afl/fl Pax7Cre ERT2 /+ mice using tamoxifen.  As a control same genotype mice 
were injected with corn oil (vehicle). Primary myoblasts was isolated and cultured 
from control (vehicle) and tamoxifen treated mice (Fig 3.14A). Pure myoblasts 
population were obtained by pre-plating technique and verified using PAX7 
staining.  Almost 97% of cells were positive for PAX7 (Fig 3.14B).  Next, G9a 
knockout was confirmed by performing real time PCR using RNA isolated from 
control and G9a null myoblasts (Fig 3.14C). These cells were used for further 
experiments. It is important to note that significant amount of cell death was 
observed in G9a null myoblasts. This observation is consistent with the other 











Figure 3.14A Myoblasts from G9a knockout mice display reduced proliferation and 
decreased expression of proliferation genes (A) Schematic showing tamoxifen 
injection regime. Mice with genotypes G9afl/fl; Pax7Cre ERT2/+ were injected with 
tamoxifen (1mg/10g of mice) for 5 consecutive days and muscles were harvested 
on 15th day.  Control (ct) mice with vehicle control (corn oil). Myoblasts were 
isolated from both control and tamoxifen injected mice.  Below panel shows 
genotype PCR results for G9a conditional knockout mice. Mice (Test mice N=1) 
with genotype G9afl/fl Pax7cre/+were taken for the experiments. First 3 lanes are 










Figure 3.14 B&C. Myoblasts from G9a knockout mice display reduced proliferation 
and decreased expression of proliferation genes (B) Pax7 staining for primary 
myoblasts isolated from G9a fl/fl; Pax7 Cre ERT2/+ mice.  (C) G9a mRNA levels 
in control (Ct) and G9a null myoblasts (G9a-/-) by real time PCR.  
 
To validate G9a role in proliferation, BrdU incorporation assay was performed with 
BrdU pulsed control and G9a null myoblasts. Consistent with our knockdown 
results, G9a null myoblasts displayed reduced proliferation as evidenced by lesser 
BrdU incorporating cells (Fig 3.14D).   
Further, control and G9a null myoblasts were analyzed for the expression of 
proliferation and differentiation genes. We found up regulation of p21 and Rb1 
while cyclinD1, DHFR and CyclinE expression was down regulated (Fig 3.14E). 
These results recapitulate the findings from the G9a knockdown studies indicating 
the importance of G9a for proliferation and cell cycle exit of myoblasts.  However, 
since these results are from single mice (N=1), these experiments have to be 
validated with G9a null myoblasts isolated from a few more G9a conditional 





Figure 3.14 D&E. Myoblasts from G9a knockout mice display reduced proliferation 
and decreased expression of proliferation genes (D) BrdU positive cells were 
counted in control (Ct) and G9a null myoblasts (G9a-/-) (N=1). Atleast 500 cells 
were counted.  BrdU and DAPI staining of cells from control and G9a-/- myoblasts.  
(E) mRNA levels of p21, Rb1, CyclinD1, DHFR and CyclinE were analyzed using 






Previous studies from our lab have identified a role for G9a in negatively regulating 
myogenic differentiation (Ling et al., 2012a, 2012b). To further understand the 
mechanisms by which G9a regulates muscle differentiation, in the present thesis 
work, we first aimed to identify the genome wide targets of G9a in skeletal muscle 
cells. To this end, we performed global gene expression analysis using microarray. 
Interestingly, we found that several cell cycle control genes were de-regulated in 
G9a knockdown cells (Fig 3.2.1). This prompted us to find out if G9a plays a role 
in proliferation of cells. Using gain-of-function and loss-of-function studies G9a 
was found to promote proliferation of cells (Fig 3.4.1 - 3.4.4).  Among the cell cycle 
target genes that we identified from the microarray, MyoD target genes (p21 and 
RB1) required for cell cycle exit were up regulated suggesting that G9a represses 
their expression. On the other hand, E2F1 target genes (cyclins, DHFR, TK) 
required for proliferation were significantly down regulated indicating that G9a 
may directly or indirectly regulate their expression. We therefore examined the 
mechanisms by which G9a differentially regulates their expression. G9a mediated 
repressive H3K9me2 on both p21 and Rb1 promoters in a methyltransferase-
dependent manner (Fig 3.6). More importantly, G9a-mediated inhibition of 
differentiation was rescued by re-expression of p21 and Rb1 indicating that 
repression of cell cycle exit contributes to myogenic differentiation defect imposed 




Next, we examined if G9a actively promotes the expression of E2F1 target genes 
that are important for cell cycle progression. G9a overexpression increased the 
expression of E2F1 target genes (Fig 3.8.1). Interestingly, G9a occupancy was not 
correlated with repressive histone methylation marks on E2F1-target genes unlike 
on p21 and Rb1 promoters (Fig 3.9). Interestingly, G9a occupancy was associated 
with H3K9ac marks instead (Fig 3.11). Furthermore, protein-protein interaction 
studies indicated that G9a is in complex with P/CAF and E2F1 in myoblasts, which 
could possibly explain G9a association with H3K9ac marks on E2F1 target 
promoters (Fig 3.12.1). Consistently, we also found that G9a overexpressing cells 
displayed higher E2F1-dependent CyclinD1 promoter activity than control cells 
(Fig 3.13). Finally, experiments with G9a null myoblasts isolated from G9a 
conditional knockout mice recapitulated our findings ex vivo (Fig 3.14). G9a null 
myoblasts displayed reduced proliferation. Cell cycle exit genes were upregulated 
and E2F1 target genes were down regulated validating our in vitro findings. 
Overall, our data support a model in which G9a both promotes proliferation and 
prevents cell cycle exit of muscle cells to block differentiation.  
4.1 G9a orchestration of myoblast cell cycle 
 
Our results demonstrate that knockdown of G9a reduced proliferation whereas it’s 
over expression increased proliferation of cells. This finding is consistent with the 
published studies which suggest that inhibition of G9a activity reduces proliferation 
of smooth muscle cells (Yang et al., 2012). siG9a cells up regulated p21 and Rb1 
expression required for cell cycle exit while down regulated E2F1 target genes 
required for proliferation. Hence we went on to examine the possibilities of G9a 
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regulation of muscle cell cycle through a) indirectly promoting proliferation by 
repressing the repressors p21 and Rb1 thus avoiding cell cycle exit or b) directly 
promoting the expression on E2F1 target genes required for proliferation.   
4.1.1 G9a regulation of cell cycle exit genes  
 
Several chromatin modifiers are shown to inhibit myogenic differentiation. For 
instance Suv39h1 and EZH2 are known to mediate repressive marks on early and 
late muscle gene promoters respectively and inhibit their expression (Caretti et al., 
2004; Mal, 2006).  However, G9a not only mediates repressive marks on myogenin 
promoter but also methylates MyoD and inhibits its transcriptional activity (Ling 
et al., 2012b). Cell cycle exit is a pre-requisite step during myogenic differentiation. 
In this study we provide evidence for a role of G9a in inhibiting MyoD mediated 
irreversible cell cycle exit. G9a mediates H3K9me2 on p21 and Rb1 promoters. 
This finding is consistent with the studies in other cell lines indicating the of 
involvement of G9a in suppressing p21 expression (Kim et al., 2009; Nishio and 
Walsh, 2004). In our ChIP assays although we amplified the MyoD binding regions 
on both p21 and Rb1 promoters, it would be meaningful to observe MyoD binding 
on their promoters upon G9a over expression.  
Up regulation of p21 during differentiation also help to reduce kinase activity of 
Cyclins/CDK complexes and as a consequence, Rb1 is hypo phosphorylated 
leading to the inhibition of cell cycle progression (Guo et al., 1995). p21 and hypo 
phosphorylated Rb1 are not only required to block proliferation, but both these 
proteins play an important role in maintaining the permanent cell cycle arrest of 
myotubes. In other words, p21 and Rb1 are involved in maintenance of post mitotic 
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state of myotubes (Mal et al., 2000). Unlike quiescent cells, differentiated myotubes 
neither can enter cell cycle nor initiate DNA synthesis upon growth factor 
stimulation. This is achieved by high expression of p21 and hypo phosphorylated 
Rb1. Although Rb1 null myoblasts differentiate, they cannot maintain permanent 
exit state. Higher frequency of apoptosis has been observed in Rb1 null myotubes 
due to endoreduplication (Zacksenhaus et al., 1996).  Absence of both p21 and Rb1 
has been shown to be capable of initiating DNA synthesis in myotubes (Andrés and 
Walsh, 1996). Indeed inactivation of p21 and Rb1 by E1A proteins leads to 
synthesis of DNA and restoration of Cyclin kinases activity in myotubes (Mal et 
al., 2000). Moreover, Suv39h1 is shown to be involved in permanent silencing 
E2F1 target genes in differentiated myoblasts (Ait-Si-Ali et al., 2004). 
Differentiated cells express low levels CyclinD1, CyclinA and DHFR. Given the 
low expression of G9a during differentiation it is unlikely that G9a is involved in 
suppressing the expression of proliferation genes. Our findings demonstrate that 
G9a overexpression promotes expression of E2F1 target genes. However, the 
possibility of G9a over expressing myotubes re-synthesizing DNA upon addition 
of growth media needs to be checked. It could be possible that G9a over expressing 
cells may not be able to maintain the post mitotic arrest. 
It is well established that, in skeletal muscle cells, p21 up regulation is dependent 
on MyoD rather than p53 (Halevy et al., 1995). Since p21 expression is MyoD 
dependent and the fact that G9a restrains MyoD activity (Ling et al., 2012b), it is 
possible that reduced p21 expression in G9a over expressing cells might be a result 
of reduced MyoD activity. Luciferase reporter experiments involving mutant 
109 
 
MyoD (K104R) which is resistant to MyoD methylation and p21 reporter construct 
would help to us in better understanding the underlying mechanisms.  Overall, we 
conclude that G9a acts as a master regulator controlling myogenic differentiation 
program by controlling proliferation and cell cycle exit of myoblasts in addition to 
its role in suppressing muscle specific genes.  
 4.1.2 G9a regulation of E2F1 target genes    
In order to find out if G9a actively promotes the expression of proliferation genes, 
we examined G9a occupancy on E2F1 target gene promoters. Remarkably, unlike 
p21 and Rb1 promoters, G9a occupancy was not correlated with repressive 
H3K9me2 marks on E2F1-target genes. These findings were particularly 
interesting because G9a is widely regarded as a repressor, nonetheless in this case 
its binding was not associated with repression. These results are consistent with the 
observation from other groups that H3K9me2 mediated by Suv39h1 was apparent 
on Rb/E2F1 target promoters in differentiating cells but not in proliferating cells 
(Ait-Si-Ali et al., 2004). Therefore, our findings prompted us to investigate if G9a 
could function as an activator of gene expression.  
Increasing number of evidences suggest G9a can act as an activator of gene 
expression and this is independent of its SET domain activity (Bittencourt et al., 
2012). Therefore, to substantiate this possibility, we pharmacologically blocked 
endogenous methyltransferase activity of G9a and examined the expression of 
E2F1 target genes. Since activator function of G9a is independent of 
methyltransferase activity, we expected no changes in the expression of 
proliferation genes. Consistent with our hypothesis we found no apparent changes 
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in the mRNA levels of E2F1 target genes. In addition, unlike on p21 and Rb1 
promoters, H3K9me2 on E2F1 target promoters were unaltered upon inhibition of 
G9a activity. Intriguingly, G9a occupancy was associated with H3K9ac marks, 
which are generally associated with activation of gene expression. A recent study 
indicated that G9a can interact with acetyl-transferase P/CAF (Oh et al., 2014). 
Therefore, we looked into the possibility of G9a interaction with activators.   
From our Co-IP interaction studies it appears that G9a is in complex with P/CAF 
and E2F1 in myoblasts and this could possibly explain G9a association with 
H3K9ac marks on E2F1 target promoters. Our results indicate that G9a is in 
complex with P/CAF, however the possibility of other co-activators such as p300 
and CARM1 needs to be investigated. Further ChIP experiments testing the 
occupancy of co-activators in the absence of G9a (siG9a cells) would give more 
insights on the involvement of G9a in recruiting co-activators to the target gene 
promoters.  
 In addition, from luciferase experiments we found that G9a overexpressing cells 
displayed higher activity of CyclinD1 promoter and this is E2F1 dependent. 
Additional luciferase experiments involving other target genes promoters such as 
DHFR and CyclinE will help substantiate the G9a role as an activator of E2F1 





4.2 G9a promotes proliferation and inhibits cell cycle exit of myoblasts: 
implications in rhabdomyosarcoma   
 
Given its role in proliferation of cells, it is not surprising to find several publications 
reporting G9a over expression in various cancers (Chen et al., 2010). 
Rhabdomyosarcoma is a common pediatric sarcoma arising due to unlimited 
proliferation of myogenic precursor cells which fail to undergo cell cycle exit 
required for myogenic differentiation (Keller and Guttridge, 2013). Data from our 
studies indicate that G9a over expression increased proliferation of cells and 
inhibited p21 and Rb1 expression required for cell cycle exit. Therefore, it is 
tempting to speculate the involvement of G9a in conditions such as 
rhabdomyosarcoma where cell cycle is de-regulated. It will be meaningful to test if 
G9a is indeed deregulated in rhabdomyosarcoma and whether it can be targeted as 




4.3 Future studies and conclusion 
 
Skeletal muscle has a remarkable ability to regenerate. During muscle regeneration 
the quiescent satellite cells are activated forming proliferating myoblasts which 
subsequently exit cell cycle and fuses to repair the injured myofibers. Our in vitro 
findings established a role for G9a in proliferation and cell cycle exit, therefore it 
is sensible to explore its role in skeletal muscle regeneration in vivo. We predict a 
possible role for G9a during muscle regeneration. Since we have G9a conditional 
knockout mice, it would be meaningful to test if G9a null satellite cells are able to 
activate and proliferate during muscle regeneration. It is noteworthy that G9a is 
found as a hetero-dimer with another lysine methyltransferase GLP, yet they are 
also known to play different roles in a number of tissue types. Either G9a/GLP both 
work together to regulate the same target genes, or they may have different cellular 
targets thus play non-overlapping cellular functions. It is possible that GLP may 
compensate for the loss of G9a in G9a conditional knockout mice. Further work 
needs to be done to understand the role of GLP in regulating muscle differentiation.  
Along similar lines, it will be interesting to explore if G9a has a role in muscle 
pathologies such as Duchene muscular dystrophy (DMD) and its mice model mdx 
where muscle is undergoing constant regeneration and degeneration process. 
Muscle integrity is compromised in muscular dystrophies due to loss of several 
genes involved in formation of sarcomere structure and maintenance of structural 
integrity. From our microarray results Myozenin (Myoz2), Myomesin (Myom3) 
and Sarcoglycans (Sgc-α,-β,-γ) genes which are involved in muscle structural 
integrity maintenance were found to be direct targets of G9a. It is well established 
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that most of these genes are driven by MEF2 transcription factors and de-regulation 
of their expression is implicated in DMD. Hence G9a could be involved in 
repression of their expression in case of muscular dystrophies.  It is also possible 
that G9a regulates MEF2 dependent transcription of these genes. Indeed, recent 
evidence suggest that G9a methylates MEF2 and regulates its activity (Choi et al., 
2014).  
Furthermore, from the microarray results calcium signaling was found to be one of 
the top pathways altered upon G9a knockdown. Calcium binding protein 
Calcequestrin 2 (Casq2), calcium release channel Ryanodine receptor1 (Ryr1) and 
calcium transporting ATPase (Atp2a1) which are involved in maintaining calcium 
homeostasis in muscle cells were found to be significantly upregulated in siG9a 
cells. Altered expression of these genes is associated with muscle pathologies 
including DMD, where intracellular calcium is overloaded in the muscle (Kunert-
Keil et al., 2014). Taken together our findings implicate a potential role of G9a in 
muscle pathologies where calcium signaling and muscle integrity is affected. 






Figure 4.4 Schematic model summarizing the mechanisms by which G9a 
regulates proliferation and cell cycle exit. G9a is present in activator complex 
and promotes proliferation of cells and also inhibits cell cycle exit by repressing 
p21 and Rb1.  
 
My thesis work provides evidence for a role of G9a in promoting proliferation of 
cells and inhibiting cells from exiting the cell cycle (Fig 4.4). Apart from G9a, other 
epigenetic modifiers could also be involved in regulating cell cycle in myoblasts. 
In the future, it will be interesting to examine by ChiP-Seq global binding of G9a; 
as well as identification of its interacting partners in myoblasts by mass 
spectrometry. Our findings indicate that G9a exists in activator complex as well as 
repressor complex in myoblasts, however, more work needs to be done to 
completely understand G9a functioning as an activator driving E2F1 target gene 
expression. Also, increasing evidence suggest possible role of epigenetic modifiers 
in pathologies involving deregulation of cell cycle such as cancer. I believe that my 
work sheds new light and identified mechanisms by which G9a regulates the cell 
cycle in muscle cells. These studies raise the possibility that its expression may be 
altered in myopathies associated with an imbalance of proliferation and 
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